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ABSTRACT 
Hepatic drug elimination is a major PK process contributing to loss of drug concentration in 
the body. The prediction of hepatic clearance (and hence drug concentrations in the body) 
requires an understanding of the physiology and mechanisms of the hepatic elimination process 
and their compilation into a mechanistic model. Several physiological models including well-
stirred model, parallel tube model and dispersion model have been developed to describe the 
hepatic elimination process and to determine how physiological variables such as blood flow, 
unbound fraction and enzyme activity may influence the hepatic clearance. However, each model 
has distinguishing advantages and limitations, which lead sometimes to very disparate prediction 
outcomes. Although hepatic drug elimination has been mathematically described by different 
physiological models, the mass transfer phenomena in the liver has not been described from a 
porous media viewpoint using local volume averaging method. The inherently porous structure 
of the liver allows us to describe the hepatic drug elimination process based on a porous media 
approach such that structural properties of the liver tissue, physico-chemical properties of the 
drug as well as transport properties associated with the hepatic blood perfusion are included in 
the model.  
Applying local volume averaging method and local equilibrium to the liver as a porous 
medium, a governing partial differential equation which takes into account liver porosity, 
tortuosity, permeability, unbound drug fraction and hepatic tissue partition coefficient, drug-
plasma diffusivity, axial/radial dispersion and hepatocellular metabolism parameters was 
developed. The governing equation was numerically solved using implicit finite difference and 
Gauss-Seidel iterative method in order to describe changes in dug concentration with time and 
position across the liver following an intravenous drug administration. The model was used to 
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predict hepatic clearance and bioavailability, which were then compared to reported 
observations.  
The predicted values of hepatic clearance and bioavailability had good agreement with the 
reported observations for high and low clearance drugs. As well, the model was able to 
successfully predict an unsteady state of hepatic drug elimination with concentration dependent 
intrinsic clearance. When statistically compared to the well-stirred, parallel tube and dispersion 
models the proposed model suggested a smaller mean squared prediction error and very good 
agreement to reported observations for eight drugs. A sensitivity analysis revealed that an 
increase in liver porosity results in a slight decrease in the drug concentration gradient across the 
liver while higher tissue partition coefficient values increase the concentration gradient. The 
model also suggested that the bioavailability was sensitive to the interaction between unbound 
fraction and intrinsic clearance. This study indicates that the liver and hepatic drug elimination 
can be successfully explored from a porous media viewpoint and may provide better mechanistic 
predictions of drug elimination processes by the liver. 
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CHAPTER 1 
BACKGROUND AND LITERATURE REVIEW 
 
1.1 Introduction 
Physiological modeling contributes substantially to drug discovery and development through 
its ability to provide better insight into mechanisms and processes attributed to pharmacokinetics 
(PK) and integrate these with pharmacodynamic (PD) processes. A mechanistic model which can 
adequately describe in-vivo physiological phenomena based on limited available in-vitro data can 
reduce the costs of animal experiments and loss in time due to poor selection of possible lead 
candidates. Such a model can perform sensitivity analyses to estimate expected PK profiles of 
new drugs in human. However, a reduction in prediction uncertainties only follow from the 
avoidance of oversimplifications or assumptions that often exclude critical determinants of the 
PK properties of a compound. Today, pharmaceutical companies focus efforts on developing 
more predictive models to describe the physiological processes more precisely so that the animal 
experiments can be reduced, refined and replaced by mathematical models. In addition, 
developing predictive physiological/mechanistic models are required for better understanding 
and analyzing pathophysiological events in the body. 
Hepatic drug elimination is a major PK process contributing to loss of drug concentration in 
the body. The prediction of hepatic clearance (and hence drug concentrations in the body) 
requires an understanding of the physiology and mechanisms of the hepatic elimination process 
and their compilation into a mechanistic model. Several physiological models, namely the well-
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stirred (WS) model, parallel tube (PT) model and dispersion (DP) model, have been developed to 
describe the hepatic elimination process and to determine how physiological variables such as 
blood flow, unbound fraction and enzyme activity may influence the hepatic clearance. 
However, each model has distinguishing advantages and limitations, which lead sometimes to 
very disparate prediction outcomes.  
Simplifications and assumptions which are made to develop and solve models are the major 
sources of uncertainties of predictions. To improve the predictability of a mechanistic model for 
hepatic drug elimination, the mathematical formulation must be consistent with the physiological 
and physical phenomena taking place in the liver. In the WS model, drug is assumed to be 
instantaneously and homogeneously mixed with the blood in the liver resulting in very uniform 
drug concentration across the liver. This idealized oversimplification adds important associated 
uncertainties in predictions by the WS model. Furthermore, the WS model ignores the 
concentration gradient across the liver which is contradictory to realistic phenomenon in the 
liver. Although the PT and DP models assume an exponential drug concentration gradient across 
the liver, these models do not take into account the influence of liver structural characteristics 
such as tissue porosity and tortuosity and tissue partition coefficients. The DP model has an 
advantage over PT model by taking into account the dispersion mechanism of the drug transport 
in the liver; however, DP model assumes that the hepatocellular metabolism rate is constant such 
that the drug concentration in hepatocytes is independent of time, and physico-chemical 
properties remain unchanged with the position across the liver. In reality, enzyme activity 
changes with the drug concentration across the liver and the drug concentration in hepatocytes as 
well as physico-chemical properties can change with time.  
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An ability to make robust predictions of drug elimination by the liver requires a mechanistic 
model that simulates real physiological events in the liver. This study focuses on the 
development and validation of a mechanistic model that represents the liver’s structural 
properties based on the concepts of porous media and considers unsteady state properties in the 
liver and concentration dependent metabolic intrinsic clearance (the inherent ability of liver cells 
to eliminate the drug) and transport mechanisms of a drug. 
 
1.2 The liver’s central role in ADME processes 
Absorption, distribution, metabolism and excretion (ADME) of a drug are the major processes 
which are quantitatively discussed in pharmacokinetics (PK). Together with physiological and 
pharmacodynamics properties, ADME processes determine the therapeutic profile of a drug. For 
example, if a drug compound is poorly absorbed in the intestine and is highly metabolized in the 
liver or rapidly excreted by the kidneys, the drug will be unable to provide its optimum 
therapeutic effects so that higher dose levels of the drug will be required to achieve sufficient 
drug concentration in the target organ for full therapeutic effect of the drug (Yanni and Thakker, 
2007). Also, if the drug is poorly lipophilic, drug distribution in a target tissue i.e. brain will be 
so poor that the drug efficacy will be low despite its high plasma drug concentration. Therefore, 
it is very important to understand and quantify ADME processes. 
Among ADME processes, hepatic drug metabolism is considered as an important process for 
drug elimination from the body and can be an important determinant of plasma drug 
concentrations. The liver is the major site of drug metabolism in the body and is responsible for 
blood detoxification whereby toxic substances in the blood are metabolized by the liver with the 
same principles as drug elimination processes. The liver is also a principal organ in the 
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maintenance of homeostasis. In order to understand the role of the liver in drug PK then, requires 
a knowledge of PK concepts and parameters, drug physico-chemical properties and liver 
anatomy, architecture and physiology. 
 1.2.1 Systemic circulation 
The systemic circulation supplies blood to all tissues throughout the body except for the 
pulmonary circulation which has its inclusive blood circulation system. The contraction of 
heart’s left ventricle forcefully pushes the fully oxygenated blood through the aorta which 
branches into many small arteries and further into arterioles and terminating into capillary beds 
throughout organs and tissues of the body. Arteries, arterioles and capillaries are responsible for 
oxygen and nutrient delivery to the tissues. Oxygen, nutrients, drug compounds as well as any 
possible toxic substances are transferred from capillaries to the tissues while wastes are 
transferred back into the capillaries which conduct the low oxygenated blood to the heart through 
venules which collect into larger vessels, the veins. Then the pulmonary circulation system takes 
over oxygenating the blood in lungs.  
In the systemic circulation, the heart supplies the oxygenated blood to the whole body via the 
arterial blood supply. The oxygenated blood is distributed in tissues and organs where the 
oxygen, nutrients and/or drug compounds are exchanged within tissue capillary beds. The 
various organs and tissues of the body receive a fraction of the cardiac output in parallel. Also, 
the blood passes through the portal circulation around the gastrointestinal tract from which 
nutrients as well as drug compounds are absorbed from the intestine into the portal blood. The 
serial nature of the blood supply from gastrointestinal tract through the portal vein to the liver 
and hepatic vein distinguishes the portal vein blood supply over the parallel nature of blood 
distribution in major organs in the body. Portal vein directs the nutrient enriched blood to the 
liver where the blood is mixed with the hepatic arterial blood in sinusoids and eventually is 
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drained into the hepatic vein. The hepatic vein joins the veins from the rest of the body towards 
the heart where deoxygenated blood is pumped to the pulmonary circulation.  
1.2.2 Distribution concepts 
The distribution process is defined as the reversible movement of drug between the systemic 
circulation and tissues of the body. The reversible drug distribution between the blood and 
tissues can be characterized by the rate of distribution and the extent of distribution. Although 
the rate of drug distribution is important, the extent of drug distribution is considered as a key PK 
process. Tissue perfusion rate, the permeability of tissue membranes, the drug binding ability 
with the blood proteins and tissue, and the lipophilicityof the drug can influence the extent and 
the rate of drug distribution.  
1.2.2.1 Volume of distribution 
Blood volume in human body is variable but roughly it can be approximated as much as 8% 
of the body weight. An average adult has about 5 L blood in the body. Unlike the definition of 
volume in chemical reaction engineering where a compound is distributed throughout a fixed 
volume, in pharmacokinetics the available space for a drug compound distribution in the body 
can change due to the disease state, physiological condition and physico-chemical properties of 
the drug. Therefore, a different measure is required to well define the space in which the drug is 
distributed in the body (Benet, 2010). Volume of distribution is the measure that describes the 
apparent volume into which a drug distributes in the body at equilibrium condition. This 
important PK has no physiological reality, rather represents a fictitious volume to identify the 
extent of drug distribution in tissues. Theoretically the distribution of a drug cannot exceed the 
total body water (vascular fluid, extracellular and intracellular fluid); however, depending on the 
physico-chemical properties of the drug (i.e. protein binding), disease state and physiological 
conditions, the volume of distribution can be smaller or much larger than the total body water 
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volume. For example, if the drug is poorly plasma protein bound, it is highly distributed in the 
body tissues rather than the plasma; therefore, the apparent volume of distribution will be larger 
than the blood volume in the body. The apparent volume of distribution is a proportionality ratio 
calculated by definition as: 
p
IV
d C
X
V                            (1.1) 
where Vd is the apparent volume of distribution (L), XIV is the intravascular (IV) dose (mg) and 
Cp is the plasma concentration at distribution equilibrium (mg/L). 
The volume of distribution is independent of drug elimination. Since systemic clearance (see 
section 1.2.3), which is the measure of elimination efficiency, and volume of distribution are 
basically independent of each other, the volume of distribution at steady state can be defined 
based on the mean residence time (MRT) of the drug in the body as (Benet, 2010): 
MRTClV sss                (1.2) 
where Vss is the volume of distribution at steady state (L), Cls is systemic clearance (L/h) and 
MRT is the mean residence of the drug in the body (h). 
Conceptually, the volume of distribution depends on several physiological determinants 
including blood volume, blood flow, partition coefficient (see section 1.2.2.3) and protein 
binding. The greater the blood volume and a larger blood flow in a tissue allows a larger amount 
of drug to be available to the tissue and a rapid drug presentation to the tissue. These factors 
enhance the extent and the rate of the drug distribution in the tissue. Also, increased drug 
lipophilicity results in a larger drug partitioning in the tissue. Increased lipophilicity can lead to 
more extensive distribution of the drug in the tissue in the presence of sufficiently high blood 
flow and volume in the tissue. When the equilibrium between the plasma and the tissue is 
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established, the unbound fraction of the drug in the tissue can influence the volume of 
distribution. Larger unbound fraction of the drug in the tissue leads to the drug transfer from the 
tissue to the plasma and it reduces the extent of drug distribution in the tissue. 
1.2.2.2 Blood protein binding and unbound fraction  
A drug can undergo binding to different blood constitutes including red blood cells, white 
blood cells and plasma proteins. Therefore, different kinds of drug concentration can be defined 
as blood drug concentration, plasma drug concentration and unbound drug concentration. In 
terms of PK processes the only fraction of drug available for crossing biological membranes is 
the free or unbound drug in blood. Therefore, increases in the unbound drug fraction (ratio of 
unbound drug concentration to total drug concentration) results in greater distribution of drug 
into tissues, which increases the volume of distribution. Due to the highly significant variability 
of plasma protein binding, a large variation in the volume of distribution can be observed for a 
single drug. In addition, diseases and drug-drug interactions can influence the plasma protein 
binding of a drug which consequently alters the volume of distribution of the drug.  
The clinical term of drug unbound fraction is defined as the ratio of the unbound drug 
concentration to the total drug concentration. If the unbound fraction of a drug is smaller than 
0.1, the drug will be considered highly protein bound and sensitive to changes in protein binding; 
however, if the unbound fraction is larger than 0.8, clinically any changes in protein binding can 
lead to insignificant influences on disposition and elimination processes (see section 1.2.5.1.3). 
Another measure which describes the extent of binding of a drug in the blood cells is blood-
to-plasma concentration ratio which is defined as the ratio of the drug concentration in blood 
cells to that in unbound plasma. Since hematocrit is defined as the volumetric fraction of blood 
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cells with respect to the blood volume, the blood-to-plasma concentration ratio can be formulated 
by definiation as: 
Hf
C
CH
Bu
p
b
)(
1 



               (1.3) 
where H is hematocrit, Cb is the total blood drug concentration, Cp is the plasma drug 
concentration, fu(B) is the unbound fraction and  is the blood-to-plasma concentration ratio. 
1.2.2.3 Equilibrium and tissue partition coefficient  
Drugs can be hydrophilic (soluble in plasma water and extra-intracellular fluids) or lipophilic 
(plasma protein bound) in nature. Most lipophilic drug compounds exhibit reversible protein 
binding interactions involving weaker chemical bonds with proteins. Within the plasma or a 
tissue compartment, lipophilic drugs undergo reversible binding with the active sites of the 
proteins to reach an equilibrium between bound and unbound drug molecules. The equilibrium 
conditions determine the plasma unbound drug concentration which is the only form of drug 
molecules to traverse the membrane and diffuse into tissues. 
The migration of plasma unbound drug molecules to the tissue depends on the degree of 
lipophilicity of molecules and the rate of presentation of drugs to the tissue by the blood flow. 
For high lipophilic drugs, the limiting factor is the blood flow while for low lipophilic with low 
solubility in the membrane the plasma-tissue exchanged is a diffusion limited process (Levitt, 
2010). The extent of the drug partitioning between the plasma and the tissue can be represented 
by the physiological measure of partition coefficient. Partition coefficient is defined as the ratio 
of drug concentration in the tissue to the unbound drug concentration in plasma when the tissue 
and the plasma are in equilibrium. Providing sufficiently high blood flow rate, the drug partition 
coefficient can be used for determination of the extent of drug distribution in a tissue; however, 
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partition coefficient is unable to evaluate how quickly the drug compound is distributed in the 
tissue. The rate of drug distribution in a tissue relies on the perfusion rate and the diffusivity of 
the drug across the membrane. 
1.2.3 Systemic clearance concepts 
After a drug compound reaches the systemic circulation, it is distributed in tissues and organs 
some of which eliminate the drug compound from the body. Drugs are mostly eliminated from 
the body either in unchanged form (parent drug) or changed form (metabolized drug). Depending 
on the water solubility or lipophilicity, the drug can be excreted by the kidneys or be metabolized 
by the liver. The kidney is the most important organ for excretion of polar drugs and their 
metabolites; however excretion may also occur via the lungs, skin, milk and bile. Liver is the 
major elimination organ responsible for the metabolism of lipophilic drugs and converting them 
into water soluble metabolites which are excreted through the kidneys. Biliary excretion of 
parent drug or metabolites may occur with a potential for their reabsorption from the intestine. In 
order to describe the efficiency of the elimination process by the major elimination organs, liver 
and kidney, a physiological measure of clearance is defined. The concept of the clearance was 
originally introduced by Rowland et al. (1973). Total body clearance or systemic clearance is 
defined as the volume of the blood cleared of drug per unit time in the body. Hepatic and renal 
clearance are defined as the volume of the blood cleared from the drug per unit time by the liver 
and kidneys, respectively.  
1.2.3.1 Elimination rate and extraction ratio 
 The systemic clearance at steady state can be calculated based on the steady state drug 
plasma concentration (Css), availability of the drug in the blood (F), administration interval () 
and the dose (X0) as follows (Rowland et al., 1973): 
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ss
s C
FX
Cl 
0
                (1.4) 
Rowland et al. (1973) and Wilkinson and Shand (1975) introduced the concept of organ 
elimination rate defined as the product of the blood flow rate by the drug concentration 
difference between the arterial and venous blood of the organ as: 
 VA CCQ                (1.5) 
 is the elimination rate, Q is the perfusion rate to the elimination organ, CA and CV are the drug 
concentrations in arterial and venous blood, respectively. Dividing Eq. (1.5) by the arterial drug 
concentration leads to the following equation describing the organ clearance as: 
 
A
VA
organ C
CCQCl               (1.6) 
where (CA-CV)/CA  is called the extraction ratio (ER) and defined as the fraction of arterial drug 
eliminated by the organ. The ER is basically a function of blood perfusion rate of the organ, the 
intrinsic ability of the organ to eliminate the drug, and the unbound fraction of the drug in the 
blood.  
Borrowing the concept of well stirred reactor model, Wilkinson and Shand (1975) assumed 
the liver as a homogenous reactor vessel in order to incorporate the above physiological factors 
into the conceptual definition of hepatic clearance. A physiologically defined hepatic clearance 
was then introduced as: 
 
intu(B)
intu(B)
H ClfQ
ClQf
Cl                          (1.7) 
where ClH is the hepatic clearance and Clint is the intrinsic clearance representing the maximum 
enzymatic metabolism capacity of the liver. Hepatic clearance has the central role in eliminating 
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lipophilic drugs. As it was discussed, the cell membranes are lipid in nature and lipid soluble 
drugs can readily traverse the membranes of tissue cells. In the same way, lipophilic drugs can 
easily enter the liver cells and undergo hepatic metabolism the efficiency of which is given by 
the hepatic clearance. 
1.2.3.2 Administration routes and pre-systemic elimination 
Drug administration can be performed through different extravascular routes, such as oral, 
rectal, subcutaneous, intramuscular, or intravascular administrations. Depending on the site of 
administration, the fraction of the drug that reaches the systemic circulation (i.e. bioavailability) 
can vary. Figure 1.1 illustrates a schematic diagram of the blood circulation system and the 
major sites of the drug administration. Administration sites 1 and 2 represent IV administration 
sites, and site 3 indicates the gastrointestinal absorption of a drug administered orally. As it can 
be seen, after the blood is circulated through the pulmonary circulation, it is pumped into the 
systemic circulation while the oxygenated blood is directed to the gastrointestinal tract where 
drug and nutrient absorption takes place. Then the blood perfuses the liver where drug 
metabolism occurs. The blood leaving the liver through the hepatic vein joins the venous blood 
coming from the general circulation in body and is conducted towards the heart. If the drug is 
administered at Site 1, providing that the lung has no contribution to the drug elimination, 
sampling from the vein associated with the general circulation can lead to a good estimation of 
systemic clearance. Likewise, if the drug is administered at Site 2 representing intra-arterial 
administration, it will be distributed in the body during its first passage without undergoing any 
elimination process. However, oral administration of a drug is followed by drug absorption in 
gastrointestinal tract, Site 3. If the administration occurs at Site 3, the drug is absorbed into the 
portal vein that directs the blood to the liver. The portal blood containing the drug compound 
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perfuses the liver where a fraction of the drug is metabolized before it reaches the systemic 
circulation. Elimination during the first passage of the drug through the liver is called the first 
pass effect which causes an error in the estimation of systemic clearance. In addition, the drug 
may be subjected to metabolism in gastrointestinal tract lumen, gastrointestinal tract mucosa, the 
intestinal and the portal vein further reducing the fraction of parent drug reaching the systemic 
circulation. Therefore, depending on the administration and sampling sites, a series of different 
organs may contribute to the first pass effect.  
 
Figure 1.1. Schematic diagram of the blood circulation and three major administration 
sites. 
Obviously the liver has a central role in ADME processes as it is quantitatively and 
qualitatively a very crucial site of drug metabolism. The first pass effect caused by the liver can 
significantly influence the plasma concentration and the efficacy of the drug. Consequently, it is 
required to have an insight into the liver anatomy and physiology as well as the mechanism of 
hepatic elimination process.  
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1.2.4 Liver anatomy and physiology 
Liver is the largest solid organ in the body and serves a critical function in blood 
detoxification, drug metabolism, bile excretion for fat breakdown, blood sugar level regulation 
and cholesterol metabolism regulation. Liver is mostly situated in the right side of the abdominal 
cavity just below the diaphragm. For adults it weighs about 1600 g in average with an average 
volume of 1602 and 1341 ml, for males and females, respectively (Anderson et al., 2000).  
Under normal conditions in human, a quarter of the cardiac output (between 1200 and 1500 
ml/min) flows through the liver every minute. The liver blood is supplied by two main sources - 
portal vein and hepatic artery. Approximately 80% of the hepatic blood flow is supplied by the 
portal vein containing partially deoxygenated but nutrient-enriched blood mostly originating 
from the gastrointestinal tract (Garcea and Maddern, 2009). The rest of the hepatic blood flow is 
supplied by the hepatic artery containing fully oxygenated blood coming from the celiac trunk 
and descending aorta. The regulation of the hepatic blood flow is performed by controlling the 
hepatic arterial flow (Bonfiglio et al., 2010). The blood supply from portal vein and hepatic 
artery are mixed in the liver and are eventually drained into the hepatic vein leaving the liver to 
travel to the heart. 
Figure 1.2 illustrates a schematic diagram of the cross section of the liver tissue. A 
microscopic view into the liver tissue reveals that the liver is composed of hexagonal cross-
sectional units called acini (Fig. 1.2a). Each hexagonal unit, acinus, is mostly made hepatocytes 
radially arranged in thin layers from inside to the outside (Fig. 1.2b). The blood from the 
branches of hepatic artery and portal vein are mixed in capillaries called sinusoids through which 
the blood flows to the central vein. Sinusoids are vascular channels made of a thin layer of 
endothelial cells which are separated from the underlying hepatocytes by space of disse. As the 
blood flows in sinusoids, the blood is filtered by the endothelial cells so that oxygen, drug 
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compounds and/or toxic substances diffuse into the space of disse from which mass transfer 
takes place into the hepatocytes (Bonfiglio et al., 2010; Teutsch, 2005). Metabolism takes place 
in hepatocytes by Phase I and Phase II enzyme-mediated processes. Bile, the secreted product of 
hepatocytes, is excreted into a network of bile canaliculi that conduct the bile to the bile ducts 
from which the bile is eventually drained into the gall bladder. Eventually, bile enters the 
proximal duodenum upon stimulation by the consumption of a meal. 
 
Figure 1.2. Schematic diagrams of the liver hexagonal units (a) and the microstructure of 
an acinus. 
1.2.5  Hepatic clearance  
The hepatic clearance is defined as the volume of the blood that perfuses to the liver and is 
cleared of drug compound per unit time. Hepatic drug elimination results from the drug 
metabolism and/or biliary excretion of drug in the liver. Drug metabolism is a process by which 
a drug is chemically changed to a metabolite with concomitant loss in pharmacological activity. 
Biliary excretion of a drug occurs due to the concentration gradient of unbound drug across the 
hepatocytes such that a higher plasma unbound drug concentration can enhance the secretary 
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transport of the drug in the liver. For lipophilic drugs which are not sufficiently excreted by 
kidneys, hepatic metabolism alters them into more water soluble compounds to be eliminated in 
urine and/or bile (Nebert and Russell, 2002).  
For many drugs liver is the most important eliminating organ such that it urges us to identify 
the physiological determinants attributed to the hepatic drug uptake and removal governing the 
hepatic clearance. These physiological determinants are hepatic blood flow, protein binding of 
the drug to the blood, inherent ability of the liver for eliminating the drug (intrinsic clearance), 
and hepatic transport mediated uptake (Pang and Gillette, 1978). Based on how the physiological 
determinants influence the hepatic clearance, the drug can be high or low in hepatic ER (section 
1.2.3.1) which is defined as the fraction of the drug at the liver inlet that is eliminated due to the 
hepatic clearance. A high or low ER drug is a drug which is highly or poorly eliminated from the 
blood, respectively, as it is passing though the liver. The interrelationship of the physiological 
determinants of hepatic clearance determines low or high hepatic ER. For example, if the 
inherent ability of the liver for eliminating a drug is poor, the hepatic ER of the drug remains low 
even if the drug presentation to the liver is high due to a high hepatic blood flow. Likewise, the 
hepatic ER of the drug can be still low if the drug is poorly delivered to the liver despite a high 
inherent ability of drug metabolism by the liver. Below the rate limiting factors influencing the 
hepatic clearance will be elaborated. 
1.2.5.1 Intrinsic clearance 
Intrinsic clearance is an indication of inherent enzyme activity in hepatocytes. Intrinsic 
clearance represents the maximal ability of hepatocytes to irreversibly eliminate unbound drug 
molecules from liver water assuming blood flow, protein binding and cell membrane 
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permeability are not rate limiting. Therefore, unbound intrinsic clearance can exceed the hepatic 
clearance in most cases.  
Generally the hepatic metabolism of drugs is mediated by hepatic Phase I and Phase II 
enzymatic metabolism in hepatocytes. The enzymatic metabolism is performed through 
oxidation/reduction, hydrolysis and inactivation of functional group of the parent drug. Phase I 
enzymes are responsible for oxidation/reduction and hydrolysis while in Phase II pathway an 
endogenous molecule is conjugated to the functional group of the parent drug molecule being 
functionally inactivated. Another important function of Phase II enzymes is the transformation of 
reactive molecules that may be produced by Phase I drug metabolism (Park et al., 2005). The 
metabolizing P450 enzymes and some Phase II enzymes are located in the smooth endoplasmic 
reticulum within the hepatocytes (Ortiz de Montellano, 1995).  
Hepatocellular metabolism can be influenced by drug-drug interactions and genetic 
polymorphisms that cause interindividual variability in hepatic drug metabolism (Tirona et al., 
2003; Martinez-Jimenez et al., 2005).  
In many cases, Michaelis-Menten kinetics describes the metabolism of a drug and intrinsic 
clearance, then, can be quantitatively determined as: 
uM
max
int CK
V
Cl                (1.8) 
where Vmax is the maximum enzyme activity capacity, KM is the inverse function of affinity 
between the drug molecules and enzyme,  and Cu is the unbound plasma drug concentration. Vmax 
is a function of the enzyme concentration at the metabolizing site while the affinity term (KM) is 
defined as the unbound drug concentration that leads to half of the maximum enzymatic 
metabolism rate. In other words, the affinity term represents the unbound drug concentration 
causing half of the active sites of metabolic enzymes to be saturated. Since it is impossible to 
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measure the unbound drug concentration at the enzyme, the estimation of KM is made based on 
the unbound plasma concentration, Cu. 
According to Eq. (1.8) for low unbound drug concentration, the intrinsic clearance can be 
assumed as a constant value of the ratio of Vmax/KM. However, if the affinity of a drug to the 
metabolic enzymes in hepatocytes is high or the concentration of drug is high, the value of KM 
will be negligible compared to the unbound drug concentration resulting in a concentration 
dependent intrinsic clearance defined as the ratio of Vmax/Cu. In this case, intrinsic clearance 
decreases as the unbound drug concentration increases. This is because the active sites of the 
metabolizing enzymes approach saturation when unbound concentration (Cu) exceeds KM.  
Since different enzymes can be responsible for metabolizing a particular drug, the overall 
metabolism process can be defined as: 

 
N
n VunM
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int CK
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,               (1.9) 
where n represents the nth individual metabolic enzyme in hepatocytes and Cu,V is the unbound 
drug concentration in the hepatic vein. Using the definition of intrinsic clearance simply given in 
Eq. (1.8), the hepatic metabolism rate can be defined as: 
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                     (1.10) 
where   is the rate of metabolism by the hepatocytes and Cp is the total drug concentration in 
plasma.  
In case of good drug delivery to the liver tissue (due to sufficient blood flow) and sufficiently 
high unbound fraction of the drug in the blood, if the drug transfer to hepatocytes is not limited 
by the hepatic tissue membrane permeability, the intrinsic clearance will be the rate limiting 
factor of the hepatic clearance. In this case, if the intrinsic clearance is low, the metabolism of 
 18
the drug remains low despite the presence of the drug compounds. Therefore, high or low 
intrinsic clearance determine high or low hepatic ER of the drug. 
1.2.5.2 Hepatic perfusion rate 
Providing that the drug is poorly bound with blood cellular components and plasma proteins 
(high unbound fraction), that passive diffusion or transporters adequately mediate drug transport 
across cell membranes, and that the hepatocellular enzyme activity is inherently high, the drug 
presentation to the hepatocytes, governed by the blood flow rate, will be the deterministic factor 
of the hepatic clearance. Thus, the faster the drug is supplied to the liver the higher rate of drug 
elimination by the liver. Therefore, the perfusion rate governs the hepatic elimination rate and 
consequently will be the limiting factor of the hepatic clearance. In this case, higher blood flow 
results in higher hepatic ER (section 1.2.3.1); however, if the intrinsic clearance is low, the 
hepatic ER will be low despite a high blood flow. In general, if other rate limiting processes 
exists, the blood perfusion rate will no longer be the limiting factor of the hepatic clearance.  
1.2.5.3 Drug unbound fraction  
For drugs with low hepatic ER (section 1.2.5) which can be associated with low intrinsic 
clearance and poor transport mediated drug uptake, the unbound drug fraction becomes a rate 
limiting factor of hepatic clearance because with a poor transport mediated drug uptake, only 
unbound drugs can traverse the membranes and be metabolized. Equation (1.10) also indicates 
that an increase in unbound fraction has a more significant role in enhancing the metabolism rate 
when the intrinsic clearance is low. In contrast, if the hepatic ER of a drug is inherently high, it 
indicates that a significant fraction of the drug at the liver inlet is well eliminated from the blood. 
Therefore, even if  the protein binding of the drug to the blood is high, it will not be a rate-
limiting factor. As the free drug is quickly metabolised in hepatocyes, unbound drug compound 
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is transferred from the plasma to the tissue. It results in a departure from equilibrium in the 
plasma where a fraction of bound drug dissociates into unbound form. The unbound drug will be 
ready to traverse the membrane to be available to the enzymes. Consequently, for high ER drugs, 
changes in unbound fraction of a drug have no influence on the hepatic clearance. For the cases 
where metabolic ER is intermediate, a region of the liver may exhibit high metabolic ER while 
another region poses low metabolic ER due to non uniformity of the distribution of enzymes and 
their activity. In this case, hepatic metabolism rate can be sensitive to the unbound fraction in the 
regions with low ER while insensitive to the unbound fraction in the regions with high ER. 
1.2.5.4 Transport mediated uptake 
The hepatic metabolism rate can be limited by hepatic uptake transporters. A hepatic intrinsic 
clearance which includes the concepts of intrinsic clearance, influx and efflux membrane 
permeability can be described as (Pang et al., 1978; Yamazaki et al., 1996): 
effluxuint
int
u,influxoverallin PSCl
ClPSCl
,
_                                             (1.11) 
where PSu,influx and PSu,efflux are membrane permeability surface area of unbound drugs across the 
sinusoidal membrane for the influx and efflux processes, respectively. If the efflux is negligible 
compared to the intrinsic clearance, the overall intrinsic clearance is given as: 
u,influxoverallin PSCl _                        (1.12) 
In this case, the hepatic uptake transporters will be rate limiting factor and subsequently 
determine the net intrinsic clearance and hepatic metabolism rate. It implies that even if the 
metabolic enzyme activity in hepatocytes is very high, the hepatic metabolism rate can be low if 
uptake transporters poorly perform the transport process. In contrast, if the efflux is considerably 
larger than the intrinsic clearance, the overall intrinsic clearance can be given as: 
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In this case, both influx and efflux processes affect the overall intrinsic clearance. In case of 
the equality of influx and efflux processes with rapid permeation of the drug across the 
sinusoidal membrane, the hepatic transporters have no rate limiting effect on the hepatic 
clearance where the net intrinsic clearance will be equal to the intrinsic clearance. 
1.2.6 Bioavailability 
It was discussed in Section 1.2.6, the oral administration is followed by the drug absorption 
from the intestinal tract into the portal vein that transports the drugs to the liver. A fraction of the 
drug can be potentially metabolized by the enzymes in the intestinal wall cells as well as in the 
blood of the portal vein. However, the majority of the drug is subject to the hepatic metabolism 
through the first passage across the liver. Following intestinal absorption the concentration of the 
drug in the portal vein is considerably high and the fraction of the drug which is subjected to 
hepatic elimination on the first pass through the liver can be significant. The fraction of the 
absorbed drug which reaches the systemic circulation is called hepatic bioavailability (FH) and 
defined as: 
ER
C
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H  11             (1.14) 
Equation (1.14) is based on the assumption of full perfusion of the portal vein in the liver. 
Equation (1.14) implies that if a drug is efficiently extracted by the liver, a small fraction of the 
drug may reach the systemic circulation if it is administered orally. For this type of drug, hepatic 
disease or drug-induced alterations, which reduce the hepatic elimination efficiency, can 
significantly increase the systemic bioavailability.  
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Oral bioavailability is defined as the fraction of the dose that reaches the systemic circulation. 
Oral bioavailability takes into account the unabsorbed fraction of the dose in the intestine as well 
as the drug loss due to the metabolism occurring in the intestine wall, portal vein and liver until 
the drug reaches the systemic circulation. 
 
1.3 Physiological model for hepatic drug elimination 
Physiological models are mathematical equations which can describe the mechanisms of the 
processes in the body based on degrees of physiological and physical simplifications and 
assumptions of the process. Unlike empirical models which are mainly based on the measured 
data, physiological/mechanistic models are developed based on the physics and the biology 
behind the phenomena. Physiological, chemical and physical properties and parameters are 
incorporated in a mechanistic model so that the model provides us a better insight into a process 
occurring in the body compared to kinetic and empirical models. 
The liver possesses a complicated physiology and structure and has been an attractive organ 
for those researchers who were trying to mathematically describe hepatic functionality for 
prediction of hepatic drug elimination. A physiologically predictive model can allow us to 
analyze the influence of physiological, pharmacological and pathophysiological events on the 
efficiency of the hepatic drug elimination. In addition, such a model can be used for estimating 
PK parameters of a new drug during the drug discovery process. Several physiological models 
have been proposed to describe the hepatic clearance. The four well known models are well-
stirred (WS), parallel tube (PT), distributed sinusoidal perfusion (DSP), and dispersion (DP) 
models while some other conceptual models have been proposed recently based on different sets 
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of assumptions and theories (Nestorov, 2007; Pang et al., 2007; Sun and pang, 2010). The 
principles of the models will be reviewed in this section. 
1.3.1 Well-stirred model 
WS model, which was inspired from the concept of well-mixed reactor for petroleum 
cracking in chemical reaction engineering, was first proposed by Gillette (1971) and then 
established by Rowland et al. (1973) and Wilkinson and Shand (1975). WS model assumes that 
the liver is equivalent to a perfectly mixed reaction vessel which is continuously stirred so that 
the fresh blood entering the liver instantaneously mixes with the blood in the liver. According to 
WS model the drug is homogenously distributed in the liver causing no concentration gradient 
across the liver. Consequently, mass balance over the liver at steady state results in (Ridgway et 
al., 2003): 
intu(B)H
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V ClfQ
CQC              (1.15) 
where CV and CA are the drug concentration at the liver inlet and outlet, respectively, and QH is 
the perfusion rate. Applying Eq. (1.15) to the definition of the hepatic clearance and 
bioavailability results in bioavailability and hepatic clearance mathematical expressions as: 
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Although the WS model is based on an idealized situation which makes the model 
oversimplified, it is easy to use and understand and can be easily applied for rough estimation of 
rate limiting factors. For example, if the intrinsic clearance is much smaller than the blood flow 
rate, the denominator of Eq. (1.17) reduces to QH and Eq. (1.17) is simplified to hepatic 
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clearance as a function of intrinsic clearance and unbound fraction. In this case for a reasonably 
high unbound fraction, the enzyme activity will be rate limiting factor of the hepatic clearance. 
On the other hand, WS model is only valid for a steady state condition and unable to take into 
account the complex network of the vascular anatomy of the liver and some important physio-
chemical properties such as tissue partition coefficient. 
1.3.2 Parallel tube model 
The concept of parallel tube (PT) model was inspired from the plug flow reactors in chemical 
reaction engineering. PT model became a better representation of the liver compared to WS 
model by assuming the sinusoids as parallel tubes with equal blood velocity and intrinsic 
clearance (Iwatsubo et al., 1996). PT model assumes that the drug compounds in the blood at the 
liver inlet enter the liver at the same time and then travel through the liver with a constant and 
equal velocity in parallel cylindrical tubes (Roberts and Rowland, 1986). Based on PT model, 
mass balance of the drug at steady state results in a nonlinear drug concentration gradient 
function as (Niro et al., 2003): 
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According to the analytical solution of Eq. (1.18), bioavailability and hepatic clearance are 
defined as: 
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Similar to WS model, the PT model can be easily used as a useful tool to assess the 
relationship between the hepatic clearance and unbound fraction, intrinsic clearance and the 
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hepatic blood flow (Wilkinson and Shand, 1975). Although PT model takes into consideration 
the non-uniform drug distribution in the liver and also offers a picture of the blood flow in the 
liver, it lacks the important transport mechanisms of diffusion, convection and dispersion for 
drug transport across hepatocellular membranes. In addition, both WS and PT model exclude the 
influence of the complex vascular network existing in the liver. 
1.3.3 Distributed sinusoidal perfusion model 
DSP model is the physiologically extended version of PT model. Unlike the PT model, the 
DSP model represents sinusoids as non-identical parallel tubes allowing the blood flow to pass 
through the liver while each tube contains a fraction of the hepatic blood flow (Iwatsubo et al., 
1996; Bass et al., 1978). According to DSP model, the hepatic bioavailability derived for the PT 
model must be expressed by each individual tube with the associated fraction of the hepatic 
blood flow rate. Since the tubes are not identical, each tube suggests its own intrinsic clearance 
as the associated dispersion and flow mixing effects all of which offer the liver heterogeneity 
which is defined as (Bass et al., 1978): 
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where Clint,i and QH,i are intrinsic clearance and blood flow rate associated with each individual 
tube, i is the tube index and N is the number of tubes. Subsequently, the flow-weighted 
bioavailability is defined as (Bass et al., 1978): 
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Although the DSP model incorporates a more realistic picture of the liver blood flow 
compared to PT and WS models, it is unable to characterize the distribution of residence time of 
the drug in the liver. In addition, similar to WS and PT models, the DSP model is valid at steady 
state. 
1.3.4 Dispersion model 
Incorporating the axial dispersion and convection of blood flow in cylindrical tubes that 
represent the sinusoids, the DP model has been widely accepted as a physiological based model 
of the liver (Roberts and Rowland, 1987). The DP model is based on the residence time 
distribution of the drug in the liver (Roberts and Rowland, 1986). Assuming a very small volume 
much smaller than the organ volume but much larger than the mean free path of molecules, the 
DP model was developed according to the variation of the amount of time spent on respective 
volumes in the organ (Roberts and Rowland, 1986). The residence time is influenced by the 
convection and dispersion effects of the blood flow. Axial dispersion is a major mass transport 
mechanism in the liver where the sinusoidal blood velocity is sufficiently high to cause a non-
uniform sinusoidal blood velocity and subsequently non-uniform residence time distribution in 
the liver. Péclet number is a dimensionless number representing the magnitude of convection 
effect over the dispersion effect of a fluid flow. The inverse of Péclet number is called dispersion 
number (Dn) as an indication of the degree of importance of the dispersion in the drug transport 
in the liver. Dispersion number is defined as: 
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Where Pe is Péclet number, dD||  is the axial dispersion coefficient, and u is the linear velocity 
along the length of L of the cylindrical tubes. When the dispersion number goes to infinity, the 
mixing frequency of the blood becomes so high that the system behaves similar to WS model. 
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On the other hand, if the dispersion number goes to zero, the system exhibits the behaviour of PT 
model (Niro et al., 2003). 
Assuming that the intrinsic clearance is independent of the drug concentration, Rowland and 
Roberts (1986) presented the variation of residence time distribution of the drug in the liver at 
steady state as (Roberts and Rowland, 1986): 
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where C is the plasma drug concentration normalized to the ratio of the drug dose to the volume 
of distribution, and Z is the dimensionless position along the liver. For the analytical solution of 
Eq. (1.24) the Dankwerts boundary condition was defined as (Dankwerts, 1952): 
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The analytical solution of Eq. (1.24) led to the hepatic bioavailability expression as (Dankwerts, 
1952): 
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where a is defined as: 
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An extension to DP model has been made by incorporating a second vascular compartment to 
the interconnecting sinusoids (Roberts and Anissimov, 1999). Although DP model takes into 
account the physiological characteristics of sinusoidal blood distribution and the associated 
residence time of the drug in the liver, it requires a general assumption whereby no parameter 
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varies along the liver and also the intrinsic clearance remains independent of drug concentration. 
In addition, the solution of DP model is valid for a steady state approximation of unbound drug 
concentration in hepatocytes. 
 1.3.5 Interconnected-tubes model 
Anissimov et al. introduced the concept of interconnected-tubes (ICT) model by modeling the 
hepatic elimination process using a large number of parallel and interconnected tubes 
interchanging the blood flow along the length of the liver (Anissimov et al., 1997). The ICT 
model takes into account the intermixing of the blood flow between sinusoids by a continuous 
and constant interchange of the drug between a set of parallel tubes at a steady state of hepatic 
elimination process. The ICT model includes a heterogeneity expression which characterizes the 
combined effects of non-uniform distributions of enzymes and flow rates between different 
sinusoids and also the intermixing effects of the blood flow between sinusoids (Anissimov et al., 
1999). The ICT model at steady state is mathematically formulated as: 
CC
dx
dC MKV e                         (1.28) 
where V is the diagonal matrix of blood velocity associated with parallel tubes, Ke is the 
diagonal matrix of the elimination rate constant, and M is the matrix of coefficients of exchange 
between tubes. According to ICT model, when the parallel tubes are poorly interconnected, the 
predicted drug concentration at the outlet is similar to that in DSP model and DP model for small 
dispersion number values.  
Although ICT model conceptualizes the interconnectivity of sinusoids and intermixing of 
blood flow in the liver, it lacks the physiological concept and parameters involved in hepatic 
clearance (i.e. membrane permeability, intrinsic clearance, tissue partition coefficient) and 
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physio-chemical properties of the drug (i.e. unbound fraction). In addition, the elimination 
coefficient is assumed constant for all the tubes along the tube lengths.  
1.3.6 Tanks-in-Series model 
Murray et al. (1987) treated the liver as a series of adjustable number of compartments (tanks) 
that allow the clearance to be dependent on blood flow. The model performs as a bridge between 
WS and PT models. When the number of tanks approaches 1, the model results become identical 
to those of WS model. For large number of tanks the model exhibits the PT model (Gray and 
Tam, 1987). The model at steady state leads to the liver outlet drug concentration and the 
bioavailability, respectively, as (Gray and Tam, 1987): 
N
H
int
inoutN NQ
ClCCC




  1                      (1.29) 
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where N is the number of tanks. For the non-linear elimination kinetics, the model is reformed 
as: 
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
          (1.31) 
where Km and Vmax are the affinity and maximum metabolism rate capacity terms. 
Like WS and PT model, the tank-in-series model is unable to physiologically describe the 
effect of dispersion and convection and intermixing effects of blood flow in the liver. However, 
the key advantage of such compartmental models is the simplicity of the equations. Also, 
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compartmental models can be easily reformulated for more complex situations such as 
heterogeneous enzyme distribution in the liver.  
1.3.7 Recent model orientations 
In recent years, researchers have focused on extending the models so that the heterogeneity in 
blood flow, enzymes, and transporters are included. Liu and Pang (2006) adopted an integrated 
approach to predict hepatic drug clearance in such a way to include the heterogeneity in enzymes 
and transporters. Fan et al. (2010) utilized physiologically based pharmacokinetic intestinal and 
liver models to predict the contributions of enzymes and transporters on intestinal availability 
and the hepatic availability of the drug. They included the impact of the influx and efflux 
transport processes to evaluate the intestine and the liver clearances (Fan et al., 2010). 
The use of the physiological models becomes difficult when unsteady state and nonlinear 
hepatic pharmacokinetics and enzyme heterogeneity exist. Hisaka and Sugiyama (1998) solved 
the fundamental equation of DM at nonlinear and unsteady state hepatic elimination of 
substances using explicit finite difference method which is less accurate than the implicit 
method. They also incorporated their method into a nonlinear least-squares fitting algorithm to 
estimate PK parameters. Their numerical model was a resemblance of a series of m 
compartments corresponding to the free or bound drug in the vascular space, blood cells, or 
Disse space, or in the cells at various radial distances from the vasculature; however, the model 
was unable to include the equilibrium condition, represented by tissue partition coefficient, 
between the tissue cells and the blood. Also the model was lacking the structural properties of 
the liver tissue (i.e. porosity, tortuosity). 
A promising approach that has emerged recently to assist scientists to analyze biological 
systems is the porous media approach. Since biological systems are made of a dispersed phase 
(i.e. cells) in a continuous phase of a fluid (i.e. blood or extracellular fluid), they can be treated 
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as porous media. In the same way, porous media principles can be applied to human 
tissues/organs where dispersed cells are separated by connective voids that allow the 
blood/extracellular matrix flow though the tissue. Porous media approach has been successfully 
applied to some biosystems including cartilage tissue engineered scaffold development (Izadifar 
et al., 2011), radio frequency enhanced extraction of anti-cancer compounds from a biological 
system (Izadifar and Baik, 2010), and thermotherapy and human thermoregulation system 
(Sherar et al., 2001; Sanyal and Maji, 2001). The liver is a highly perfused tissue which can be 
appropriately treated as a porous medium. Charles et al. (1989) introduced a three dimensional 
finite element model for the fluid flow and mass transfer in the liver based on the principles of 
porous media. Assuming a Reynolds number smaller than 1, they adopted the principles of 
porous media where the blood flow in the liver was a creeping flow described by Darcy’s law. 
They developed the momentum equation according to the hydraulic permeability of the tissue. 
For the mass transfer equation, they assumed the Peclet number to be greater than 1 whereby the 
dispersion could be neglected due to the dominant convection. The mass transfer governing 
equation was unable to describe the hepatocellular drug metabolism which can be linear or 
nonlinear. In addition, the model was unable to include the tissue-blood equilibrium of the drug 
species but the drug transfer from the blood to the cells was described based on the cell 
membrane permeability. The lack of information of tissue partition coefficient, the axial 
dispersion and hepatocellular metabolism in the model were significant downsides of the 
proposed model.  
The following section brings a brief overview of some important porous media concepts to 
the readers. It will be followed by introducing the objective of this research which is to apply 
porous media concepts to mathematically describe hepatic drug elimination process. 
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1.4 Porous media concepts and applications in biomedical engineering 
Porous medium is defined as a solid matrix with interconnected voids filled with a fluid, 
liquid or gas or both. The solid matrix can be particles of the soil, the polymer matrix of a tissue 
engineering scaffold, a packed bed of fertilizer particles, or a vascularised tissue. A porous 
medium is generally characterized by porosity, length scales, tortuosity and permeability. 
Modeling of transport phenomena of porous media made significant progress recently and the 
models have been used for different applications in engineering and science. In this section the 
concepts and biological applications of porous media are reviewed and discussed. 
1.4.1 Representative elementary volume (REV) 
A porous medium is a solid matrix consisting of a solid phase and spaces among solid 
particles which can be filled with a fluid, liquid or gas. The range of pore size of porous media 
can vary from molecular size (nm) to centimetre. When a solid matrix cannot be described within 
a pore size, a REV with a characteristic length of l and volume of Vl is defined to represent the 
structure of the solid matrix. REV is defined as the smallest differential volume of a porous 
medium that results in statistically meaningful average properties of the porous medium (Darcy, 
1856). Figure 1.3 schematically and graphically depicts the concept of a REV. As it can be seen, 
a very small volume located in the pore of the porous medium (Fig. 1.3a) results in the fluid 
volumetric fraction of 1 as indicated in Fig. 1.3b. As the size of the volume increases, more solid 
fraction is included in the volume causing the fluid volumetric fraction to decrease. As it is 
shown in Fig. 1.3 b, the variation of the fluid volumetric fraction fluctuates with the size of the 
volume; however, it becomes insensitive to any increase in the size of the volume when the 
volume of Vl is sufficiently large. The volume of Vl, which is called REV, is the smallest volume 
the property of which can represent the property of the porous medium.  
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Figure 1.3. Schematic diagram of representative elementary volume and the variation of 
the medium property with the size of representative elementary volume. 
1.4.2 Local volume averaging method (LVA) 
Averaging properties of the medium over REV is called local volume average properties of 
the medium. If a property of one of the phases of the REV is averaged over the volume of the 
phase, it is called intrinsic phase averaged property. Averaging the governing equations of mass, 
heat and momentum transfer over the REV with the application of local volume average 
properties is called the LVA method to describe transport phenomena in porous media.  
1.4.3 Length scales in porous media and LVA validity condition  
In order to apply the concept of LVA method to mathematical modeling of transport 
phenomena in a porous medium, the length scales of the medium must satisfy the validity 
condition of LVA method. Figure 1.4 illustrates the characteristic lengths of a typical porous 
medium. The characteristic lengths of a porous medium are: the linear dimension of the porous 
medium system (L), the REV characteristic length (l), the pore size (dp), and Brinkman screening 
distance (K1/2), which is an indication of the boundary layer thickness of the fluid flowing in 
pores of the medium.   
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Figure 1.4. Schematic diagram of a porous medium and the associated length scales. 
 
The validity condition of LVA method is: 
K1/2<<dp<l<L                        (1.32) 
where K is the permeability of the porous medium. Permeability is an important property and a 
measure of the flow conductivity in the porous medium. According to Darcy law, the fluid 
velocity is linearly related to the pressure gradient across the porous medium with a 
proportionality constant of the ratio of permeability to the fluid viscosity (Darcy, 1856). A 
porous medium is also characterized by tortuosity which is defined as the ratio of the length of 
the tortuous path to the straight length between both ends of the porous medium. A plain medium 
(a non-porous medium) possesses a tortuosity of 1 while for a porous medium the tortuosity is 
greater than 1. Tortuosity has a great impact on the molecular diffusion and heat conduction 
across a porous medium. 
1.4.4 Application of LVA method to biological systems 
LVA method has been used for developing mechanistic models of numerous biological 
systems. Izadifar et al. (2011) applied LVA method to develop a mathematical model for mass 
transfer of nutrients and chondrocyte proliferation in a cylindrical cartilage scaffold. These 
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researchers developed two sets of partial differential equations for glucose transfer across and 
cell proliferation porous scaffold based on the LVA method. The governing equations were 
simultaneously solved using numerical methods to analyze and predict the required time for cell 
seeding in biomanufacturing fabrication and superficial cell seeding methods (Izadifar et al., 
2011). Izadifar and Baik (2010) developed a dynamic mathematical model of heat transfer to 
describe the radio frequency enhanced extraction of podophyllotoxin from a porous biological 
packed bed based on LVA method. Their model had very good agreement with the experimental 
data indicating that the LVA based model could be successfully used for optimizing the 
bioprocess. Sanyal and  Maji (2001) treated three layers of the skin and subcutaneous region as 
porous media in an attempt to find the analytical and numerical solution of bioheat transfer 
equation to describe the human thermoregulation system under variable physiological parameters 
and atmospheric conditions.  Nicholson (2001) developed a mass transfer model based on porous 
media principles to describe glucose and oxygen transfer from the vascular system to the brain 
cells as well as the drug delivery to the brain. He characterized the brain tissue and diffusion-
generated concentration distribution by the porosity and tortuosity of the brain. His model 
revealed that an increase in the tortuosity and a decrease in the porosity have significant effects 
in reducing the effective mass diffusivity of molecules in the brain (Nicholson, 2001). Lei et al. 
(1998) developed a complex model for mass transfer phenomenon in transvascular exchange and 
extravascular transport of fluid and macromolecules for a spherical tumor. They treated both 
tissue and the tumor as porous media with a Darcy velocity of the blood flow while the 
interstitial fluid was assumed to obey Starling law. Their model proved to have good agreement 
with observations. 
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The liver is a highly perfused organ with a porous structure of hexagonal units called acini. 
The blood flow conductivity of the liver tissue is determined by the interconnected sinusoids in 
the liver. Although hepatic drug elimination has been mathematically described by different 
physiological models, as discussed in Section 1.3, the mass transfer phenomena in the liver has 
not been described from a porous media viewpoint using LVA method. The inherently porous 
structure of the liver allows us to describe the hepatic drug elimination process based on a porous 
media approach.  
 
1.5 Research objective 
The main objective of this study was to develop and validate a porous media model based on 
local volume averaging (LVA) method for describing the time dependent drug concentration 
gradient across the liver as well as drug hepatic elimination rate, hepatic clearance and hepatic 
bioavailability. LVA method will integrate the properties and mass transfer equations as well as 
the hepatocellular metabolism characteristics over the REV of the liver tissue. The main 
difference between LVA method and the multi-dimensional method proposed by Charles et al. 
(1989) is that LVA method will include the axial/radial dispersion, local volume equilibrium 
between tissue and blood, and time-space dependent hepatocellular metabolism in the porous 
media model while the model proposed by Charles et al. (1989) excluded these important events. 
In Chapter 2, the theoretical background of the porous media approach will be explored. The 
liver structure will be characterized based on four characteristic length scales and LVA validity 
condition will be evaluated. Then, the mathematical modeling procedure will be presented from 
fundamental beginnings where the mechanisms of mass transport are elaborated in a differential 
element of the liver tissue. The governing partial differential equation of drug transport and 
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nonlinear/linear drug elimination processes will be derived followed by the details of the 
numerical solution of the model. The stability and consistency of the numerical solution will be 
examined and simulation results will be compared to experimental data as well as the predicted 
values from other models. At the end of Chapter 2, it will be shown how the proposed model can 
be applied to perform the sensitivity analyses of hepatic drug elimination as well as the drug 
distribution in the liver with respect to different physiological conditions. 
This study will assess two major hypotheses. The first hypothesis is that characteristic length 
scales of the liver tissue including sinusoidal diameter (pore size), acinus diameter and tissue 
equivalent length scale can satisfy LVA validity condition such that LVA method can be applied 
for modeling the hepatic drug elimination process. The second hypothesis is that the hepatic drug 
elimination process can be successfully described by a mechanistic model which is based on the 
porous media approach of LVA. The validity of the hypothesis will be assessed using 
observations reported by other researchers for eight different drugs with a wide range of intrinsic 
clearance and unbound fraction.  
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Abstract 
Applying local volume averaging method and local equilibrium to the liver as a porous 
medium, a governing equation taking into account liver porosity, tortuosity, permeability, 
unbound drug fraction and hepatic tissue partition coefficient, drug-plasma diffusivity, 
axial/radial dispersion and hepatocellular metabolism parameters was developed. The governing 
equation was numerically solved to predict changes in dug concentration with time and position 
across the liver and the hepatic clearance and bioavailability following an intravenous drug 
administration. The predicted values of hepatic clearance and bioavailability had good agreement 
with the reported observations for high and low clearance drugs. As well, the model was able to 
successfully predict an unsteady state of hepatic drug elimination with concentration dependent 
intrinsic clearance. When statistically compared to the well-stirred, parallel tube and dispersion 
models the proposed model suggested a smaller mean squared prediction error and very good 
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agreement to reported observations for eight drugs. A sensitivity analysis revealed that an 
increase in liver porosity results in a slight decrease in the drug concentration gradient across the 
liver while higher tissue partition coefficient values increase the concentration gradient. The 
model also suggested that the bioavailability was sensitive to the interaction between unbound 
fraction and intrinsic clearance. This study indicates that the liver and the hepatic drug 
elimination can be successfully explored from a porous media viewpoint and may provide better 
mechanistic predictions to drug elimination processes by the liver. 
 
2.1 Introduction 
The liver plays a very important role in the elimination of drugs, toxic substances, and 
harmful biochemical products produced by the body. The liver receives nutrient rich but poorly 
oxygenated blood from the intestines via the portal vein and oxygenated blood from the hepatic 
artery accounting for 75% and 25% of total blood supply, respectively. Both blood supplies 
perfuse to each hexagonal functional unit called acinus in which portal and arterial blood are 
mixed in the smallest acini vessels called sinusoids and in which mass exchange takes place 
between blood and hepatocytes. 
The liver’s essential role in the maintenance of homeostasis as well as drug and toxin 
elimination in the body demands a detailed understanding of liver function. Mechanistic models 
that effectively describe liver function can play an important role in understanding and predicting 
drug concentration and hepatic metabolic performance. Different physiological models have 
been developed for the liver based on different degrees of simplifications and assumptions. The 
well-stirred (WS) model and the parallel-tube (PT) model are the two most commonly used 
models describing drug elimination by the liver (Pang and Rowland, 1977). These models are 
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based on idealized situations of blood flow and drug distribution in the liver with an implicit 
assumption that the partition ratio of free drug between sinusoidal blood and hepatocytes is 
constant. In the well-stirred model, the drug is assumed to be instantaneously and 
homogeneously mixed with the blood in the liver resulting in very uniform drug concentration 
across the liver. Bass et al. (1977) and Forker and Luxon (1977) developed a distributed model 
representing blood flow in parallel tubes where each tube transports a volumetric fraction of total 
blood flow as determined by a distribution function. Roberts and Rowland (1986) developed a 
physiological-based dispersion (DP) model which was based on the residence time distribution 
of the drug in the liver where the distribution of residence times depended upon the axial 
dispersion. The analytical solution of the DP model requires a general assumption whereby no 
parameter varies along the length of sinusoids and intrinsic clearance due to metabolic enzyme 
activity or transporter function are independent of drug concentration. In addition, it assumes a 
steady state approximation of unbound drug concentration in hepatocytes. Although the DP 
model takes into account hepatocellular permeability of drugs, it fails to consider the hepatic 
tissue partition coefficient and tissue structural characteristics such as porosity and tortuosity. 
Hisaka and Sugiyama (1998) solved the fundamental equation of DM at nonlinear and unsteady 
state hepatic elimination of substances using explicit finite difference method which is less 
accurate than the implicit method. They also incorporated their method into a nonlinear least-
squares fitting algorithm to estimate PK parameters. Their numerical model was a resemblance 
of a series of m compartments corresponding to the free or bound drug in the vascular space, 
blood cells, or Disse space, or in the cells at various radial distances from the vasculature; 
however, the model was unable to include the instantaneous equilibrium conditions (i.e. tissue 
partition coefficient) between the tissue cells and the blood. In addition, the structural properties 
 44
of the liver tissue (i.e. porosity, tortuosity) were not included in the model. Charles et al. (1989) 
introduced a three dimensional finite element model for the fluid flow and mass transfer in the 
liver based on the principles of porous media. Assuming a Reynolds number smaller than 1, they 
adopted the principles of porous media where the blood flow in the liver was a creeping flow 
described by Darcy’s law. They developed the momentum equation according to the hydraulic 
permeability of the tissue. For the mass transfer equation, they assumed the Peclet number to be 
greater than 1 where the dispersion could be neglected due to the dominant convection. The mass 
transfer governing equation was unable to describe the hepatocellular drug metabolism which 
can be linear or nonlinear. In addition, the model was unable to include the tissue-blood 
equilibrium of the drug species but the drug transfer from the blood to the cells was described 
based on the cell membrane permeability. The lack of information of tissue partition coefficient, 
the axial dispersion and hepatocellular metabolism in the model were significant downsides of 
the proposed model. 
The main objective of this study is to develop and validate a porous media model based on 
local volume averaging (LVA) method for describing the time dependent drug concentration 
gradient across the liver as well as drug hepatic elimination rate, hepatic clearance and 
bioavailability. Unlike the DP model, the proposed model takes into account an unsteady state 
drug concentration in the liver as well as concentration dependent hepatocellular metabolism 
which varies with time and position along the liver. In addition, unlike WS, PT and DP models, 
the proposed mechanistic model includes structural characteristics of the liver (i.e. porosity and 
tortuosity). Finally, the model considers transport properties such as axial/radial dispersion, 
molecular diffusion, and hepatic tissue partition coefficient. The model was used for prediction 
of hepatic clearance and bioavailability as well as the drug concentration gradient across the liver 
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with time. Also, a sensitivity analysis was performed using the model to investigate the influence 
of different parameters on drug distribution in the liver and hepatic elimination. The flexibility of 
the model was demonstrated through its coupling with an absorption model to simulate the 
dynamic changes in drug distribution in the liver associated with the gastrointestinal absorption 
process. 
 
2.2 Theory 
2.2.1 Local Volume Averaging (LVA) method 
A porous medium is a solid matrix consisting of a solid phase and spaces which can be filled 
with a fluid. As a highly perfused tissue the liver can be treated as a porous medium consisting of 
sinusoidal spaces filled with blood and a matrix of hepatocytes. In porous media when a solid 
matrix cannot be described within pore size, a representative elementary volume (REV) with a 
characteristic length of l and volume of Vl is defined to represent the structure of the solid matrix. 
A REV is defined as the smallest differential volume resulting in statistically meaningful average 
properties of the porous medium. As shown in Figure 2.1, the liver tissue is composed of 
repeating hexagonal units of acini. Each hexagonal unit, or acinus, consists of hepatocytes lining 
blood-filled sinusoids of diameter, dp. Blood from branches of the portal vein and hepatic artery 
is mixed and flows through the sinusoids to subsequently drain into the central vein. Substances 
(e.g. oxygen, drugs) are transferred from the blood to the hepatocytes during flow through the 
sinusoids. For the liver an acinus can be considered as a REV where averaging a property over 
the volume of an acinus (Vl) is called local volume averaged property defined as: 
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Figure 2.1. Schematic diagram of the liver microstructure with the associated length scales. 
dV
V
lVl
  1                                          (2.1) 
where   is the property of interest and   is the local volume averaged property. 
The method that uses local volume averaged transport governing equations and properties 
over the REV is called local volume averaging (LVA) method. In order to apply LVA method, 
the validity of LVA must be verified by the following condition as: 
 
Lldk pphys 2/1                           (2.2)    
where physk is the sinusoidal based permeability (m2), dp is the average sinusoidal diameter (m), l 
is the length scale of REV (m), and L is the equivalent length of the liver tissue (m). Since a liver 
approximately consists of one million acinii (Jones and Spring-Mills, 1988), the REV 
characteristic length of a normal liver with a volume of 1223 ± 217 cm3 will be approximately 
600 m (Zhou et al., 2007). Considering that the sinusoidal based permeability is 3.310-13 m2 
(Smye et al., 2007) and the sinusoid diameter of the liver tissue with a length of ~20 cm is as 
small as a few cells (i.e. <60 m), the validity condition of LVA is satisfied as 5.710-7<<610-
5<610-4<<210-1. 
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2.2.2 Mathematical Modeling 
The geometry of the liver was simplified so that a slab with the same thickness and volume as 
the liver could represent the liver tissue (Figure 2.2). Having an average volume and thickness of 
the liver, the length of the representative slab was calculated as the equivalent length of the liver. 
Figure 2.2a illustrates the liver representative slab with an equivalent length of L where the blood 
enters the slab through the portal vein and hepatic artery and leaves the tissue through the hepatic 
vein. Figure 2.2b shows the schematic diagram of a porous differential element with a length of 
x. Transport of drug into/out of the porous differential element is due to the molecular 
diffusion, axial/radial dispersion, and advection.  
 
Figure 2.2. Schematic diagram of the simplified geometry (a) and the porous differential 
element (b) of the liver. 
As the blood flows through the sinusoids (pores of the element) with a Darcy velocity, the 
unbound drug in plasma is assumed to be locally in equilibrium with the hepatocytes within 
which the drug undergoes hepatocellular metabolism at a metabolism rate described by definition 
as: 
p
Buvivoinintmet CfClm )(_ˆ                                     (2.3) 
where metmˆ is the hepatocellular metabolism rate normalized by liver tissue volume (mgs-1ml-1), 
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fu(B) is the unbound fraction of the drug in the blood, Clint-in vivo is the average value of in vivo 
hepatic intrinsic clearance (s-1), and
PC is the local volume averaged drug concentration in 
plasma (mgml-1). In addition to Eq. (2.3), the concentration dependent hepatocellular metabolism 
can be described by Michaelis–Menten equation as:  
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                          (2.4) 
where Vmax and KM are the maximum metabolism rate capacity (mgs-1ml-1) and affinity term 
(mgml-1), respectively. Applying a transient mass balance over the differential element with a 
thickness of x results in: 
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where DAB is the molecular diffusion of the unbound drug in the plasma (m2s-1),  is the 
sinusoidal based porosity,   is the sinusoidal based tortuosity, fu(B) is the unbound fraction of the 
drug in the blood, A is the cross sectional area perpendicular to the hepatic blood flow into the 
liver tissue representative slab (m2), x is the position of the drug compound in the liver (m), .metm  
is the hepatocellular metabolism rate (mgs-1), K* is the liver tissue partition coefficient, t is time 
(s), dD  and dD ||  are axial and radial dispersion coefficients (m
2s-1), respectively, and Bu is the 
blood Darcy velocity (ms-1) which can be given as: 
A
Q
u hB                           (2.6) 
where Qh is the hepatic perfusion rate (mls-1). In addition to Eq. (2.6), having the sinusoidal 
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permeability of the liver tissue and the blood pressure drop across the liver, the blood Darcy 
velocity can be obtained as: 
L
Pku physB
                (2.7) 
where P/L is the linear blood pressure gradient (Pas.m-1) across the liver and  is the blood 
viscosity (Pas.s). 
The partial differential governing equation of drug transfer, Eq. (2.8), then, is derived by 
substitution of the metabolism term by Eq. (2.3) and division of Eq. (2.5) by the volume of the 
differential element followed by simplification of the equation and letting x and t go to zero: 
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where metmˆ  is the hepatocellular metabolism rate normalized by the liver tissue volume (mgml-1 
s-1) given by Eqs. (2.3) and (2.4) for a constant and nonlinear hepatocellular metabolism, 
respectively. Accordingly, the intrinsic clearance function can be defined as: 
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As indicated in Eq. (2.8), the time dependent drug concentration in both hepatocytes and 
plasma is described by the accumulation term on the right side of the equation. The liver 
structural characteristics of porosity and tortuosity are included in the governing equation while 
the blood Darcy velocity and the axial dispersion coefficient takes into account the influence of 
the tissue permeability. The initial plasma drug concentration of the liver tissue is zero and is 
defined as: 
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0)0,( txC P                                                                                                                     (2.10) 
If instantaneous drug distribution in the body occurs following intravenous (IV) bolus 
injection of drug then the ratio of the IV dose (X0) to the volume of distribution (Vd) determines 
the plasma drug concentration at the blood entry to the liver. At the liver inlet and outlet 
boundaries the convective mass flow predominates and diffusion and dispersion are assumed to 
be insignificant. Consequently, the boundary conditions can be described as:  
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When the drug distribution within the liver is complete, the model can predict the plasma 
unbound drug concentration just at the liver outlet in the hepatic vein. Knowledge of the drug 
concentration at the inlet and outlet of the liver allows the calculation of the hepatic clearance 
(Clh-LVA) as: 
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where 
P
uC is the local volume averaged unbound drug concentration (mgml-1), L is the 
equivalent length of the liver (m). In order to compare the proposed model to other models, the 
hepatic clearance was calculated for WS, PT and DP models, respectively, as follows (Ito and 
Houston, 2004): 
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where Clh-WS, Clh-PT  and Clh-DP  (s-1) are the hepatic clearance suggested by WS, PT and DP 
models, the dispersion number of Dn in Eq. (2.15) is 0.17 and a is defined as (Robert and 
Rowland, 1986): 
h
ninvivointtBu
Q
DClVf
a  )(41                                 (2.16) 
where Vt  is the volume of the liver tissue (ml) and can be calculated for males and females by  
Eqs. (2.17) and (2.18), respectively, as a function of body weight as (Anderson et al., 2000): 
)10log(5.2103.17415 cbt aWV           (2.17) 
bt WV 5.14389                                         (2.18) 
where Vt is the liver volume (ml), Wb is the body weight (kg) and ac is the number of drinks per 
day. Because of a poorer correlation between liver volume and body weight suggested by the 
allometric model (Swift et al., 1978), Eqs. (2.17) or (2.18) were used for calculation of liver 
volume in this study. For nonalcoholic males and females, the average values of the liver volume 
are 1602 and 1341 ml, respectively (Anderson et al., 2000). With estimates of hepatic clearance 
(Clh) and the hepatic perfusion rate (Qh), the bioavailability is calculated as (Roberts and 
Rowland, 1986): 
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2.2.3 Numerical Solution of the model 
Numerical solution of the model required a number of simplifying assumptions as follows:   
i) Extrahepatic clearance of the drug was negligible;  
ii) Biliary excretion of parent drug was negligible;  
iii) Following IV administration drug undergoes instantaneous distribution in the body such that 
plasma drug concentration at the liver inlet could be assumed as the ratio of IV dose to the 
volume of distribution of the drug; 
iv) Blood concentration to plasma concentration ratio of the drug was unity; 
v) The unbound fraction of the drug in the blood remained unchanged with time;  
vi) Radial dispersion was negligible compared to advection and axial dispersion.  
The liver representative slab was divided into N+1 nodes where N was the node at the liver 
outlet and N+1 was a fictitious node just in the hepatic vein. Then, the governing equation, Eq. 
(2.8), was discretized using implicit finite difference method. Rearranging the finite difference 
equations resulted in the following system of algebraic equations as: 
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where i is the node index, j is the time step index, C represents the plasma unbound drug 
concentration, and the coefficients of  ,  ,  , and   are defined as: 
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The mesh size was determined based on the sensitivity analysis of the drug concentration 
gradient across the liver at the time when drug distribution in the liver reaches a distribution 
equilibrium (i.e. at 100 s) with respect to the number of nodes. Time step size was determined 
based on the sensitivity of the stability, accuracy and the speed of solution with respect to the 
time step size at different mesh size. Gauss-Seidel iterative method with a convergence criterion 
of 10-6 was used for solving the system of algebraic equations simultaneously.  
2.2.4 Pharmacokinetic and structural parameters for the simulation 
Simulation was performed for eight drugs, naloxone, lidocaine, metoprolol, verapamil, 
caffeine, timolol, diazepam, and phenacetin (Shibata et al., 2002), at a hepatic perfusion rate of 
1500 mlmin-1 and a sinusoidal porosity of 0.12 (Smye et al., 2007) for a time-course of 200 s 
following a 5 mg IV dose of each drug. The tortuosity of the liver tissue was calculated 
according to the tortousity of porous media consisting of layer by layer parallel rods as (Perry 
and Green, 1997): 
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Table 2.1 shows the pharmacokinetic properties of each drug used for the simulation. The 
unbound fraction and intrinsic clearance of the drugs vary from 0.013 (diazepam) to 0.883 
(metoprolol), and from 0.3 (diazepam) to 154.9 (nalaxone) mlmin-1kg-1, respectively. Lidocaine, 
with a tissue partition coefficient of 0.61 (Joseph et al., 2001), was chosen as a candidate for the 
simulation of drug distribution across the liver as well as for sensitivity analyses. 
Table 2.1. Pharmacokinetic parameters of drugs used in the simulation of hepatic 
clearance. 
Drug  Unbound fraction 
Intrinsic clearance 
(mlmin-1kg-1) 
Volume of distribution 
(Lkg-1) 
Lidocaine 0.615 a 29.8 g 3.00 h 
Nalaxone 0.559 b 154.9 b 2.64 i 
Metoprolol 0.883 c 17.8 c 4.5 j 
Verapamil 0.280 d 31.0 d 4.63 k 
Caffeine 0.650 e 1.7 e 1.06 l 
Phenacetin 0.600 f 127.5 f 1.55 m 
Timolol 0.400 o 7.7 o 3.5 n 
Diazepam 0.013 p 0.3 p 1.57 q 
a Jacobi et al., 1983; b Asali and Brown, 1984; Holford, 1998; c Regardh et al., 1981; d 
Deshmukh and Harsch, 2011; e Blanchard, 1982; f, m Raaflaub and Dubach, 1975; g Wing et 
al., 1984; Remmel et al., 1991; h Ikeda et al., 2010; i Glass et al., 1994;; j Hardman et al., 
1996; k McAllister and Kirsten, 1982; l Lelo et al., 1986; n Else et al., 1978; o Holford, 1998; p 
Divoll et al., 1983; q Norman et al., 1997 
 
2.3. Results and discussion 
In order to determine the optimum mesh size, the sensitivity of the drug concentration 
gradient across the liver to the grid size at 100 s was investigated. Figure 2.3 depicts the plasma 
drug concentration with the liver equivalent length for different mesh grid numbers. According 
to Figure 2.3, the drug concentration gradient across the liver increases sharply with the number 
of nodes up to 200. Thereafter, the concentration gradient increases marginally up to 350 nodes 
and then remains relatively unchanged. A mesh size of 0.63 mm equivalent to 350 nodes was  
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Figure 2.3. Sensitivity analysis for determination of optimum mesh size for the numerical 
solution. 
adopted for the numerical solution. According to accuracy and speed of solution, which were 
performed for different time step sizes of 0.1, 1, 5, and 10 s, a time step size of 1 s was adopted 
for the numerical solution. 
 Figure 2.4 illustrates the correlation between the predicted values of hepatic clearance and 
observed values reported by Shibata et al. (2002) for eight drugs at a perfusion rate of 1500 
mlmin-1for a 70 kg male subject. The coefficient of determination (R2) of 0.91 indicates a good 
agreement between predicted and experimental values. The proposed model seems to 
underestimate the hepatic clearance of timolol and verapamil while overestimating phenacetin 
(Figure 2.4). This may be due to variability in the measured values of unbound drug fraction and 
intrinsic clearance, which will enhance uncertainty in the predicted values of hepatic clearance. 
For instance, the genetic polymorphism associated with timolol hepatocellular metabolism 
segregates a portion of the population into a poor metabolizer phenotype and estimates of timolol 
hepatic clearance causing a significant variability in the population. Since the pharmacokinetic 
properties used for the simulation are not population based, the predicted values may not capture 
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Figure 2.4. Predicted values of hepatic clearance from Porous Media based model versus 
reported observations (Shibata et al., 2002) for eight drugs. 
the population variability and, hence, are associated with greater uncertainty in the estimation of 
the hepatic clearance of timolol. 
Table 2.2 presents the observed values of the hepatic clearance of eight drugs as well as the 
predicted values from the proposed porous media (PM) based model and the WS, PT and DP 
models. Table 2.2 indicates that PM model predictions are mostly consistent with PT and DP 
models and relatively less consistent with the WS model, likely due to the oversimplifications 
associated with WS model. A comparison of observed values to the predicted values of the 
models indicates that the PM model is less predictive of caffeine hepatic clearance while more 
predictive for diazepam hepatic clearance relative to the WS, PT and DP models.  
Figure 2.5 illustrates the correlation between the predicted and the reported values of 
bioavailability for eight drugs at a hepatic perfusion rate of 1500 mlmin-1 for a 70 kg male 
subject. The coefficient of determination (R2) of 0.80 indicates a relatively good agreement 
between predicted and observed values of bioavailability, although PM model overestimates 
verapamil and timolol and underestimates naloxone, metoprolol, and phenacetin. Since the 
bioavailability is calculated based on the hepatic clearance, Eq. (2.19), the error associated with 
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Table 2.2. Comparison of model predictions with observed values of the hepatic 
clearance associated with seven drugs. 
 Model predictions of ClH (ml/min.kg) Observations
Compound PM WS PT DP reported a 
Naloxone 20.34 17.18 21.05 20.20 24.8 
Verapamil 7.51 6.18 7.14 6.84 11.8±5.0 
Phenacetin 20.00 16.74 20.83 19.83 19.6±4.5 
Lidocaine 12.27 9.88 12.32 11.51 12.5±1.5 
Metoprolol 11.63 10.14 12.70 11.86 10.8±1.5 
Caffeine 2.83 1.05 1.08 1.07 1.0±0.4 
Timolol 4.29 3.11 3.28 3.35 7.7±1.2 
Diazepam 0.47 0.01 0.01 0.01 0.3±0.1 
a Shibata et al., 2002 
 
the predicted hepatic clearance accumulates in the predicted values of bioavailability. For 
instance, predicted hepatic clearance accumulates in the predicted values of bioavailability. For 
instance, underestimation of hepatic clearance of verapamil and timolol leads to the 
overestimation of their bioavailability. Furthermore, the literature reports bioavailability 
following oral administration with reductions in bioavailability resulting from intestinal and 
hepatic mechanisms. The PM model only accounts for drug loss by the liver in its prediction of 
bioavailability.  
R2 = 0.80
0
0.2
0.4
0.6
0.8
1
1.2
0 0.2 0.4 0.6 0.8 1
Observed values of bioavailability
Pr
ed
ic
te
d 
va
lu
es
 o
f b
io
av
ai
la
bi
lit
y
Naloxone
Verapamil
Phenacetin
Metoprolol
Caffeine
Lidocaine
Timolol
Diazepam
 
Figure 2.5. Predicted values of bioavailability from Porous Media based model versus 
reported observations (Shibata et al., 2002)  for eight drugs. 
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Table 2.2 presents the observed values of bioavailability of eight drugs as well as the 
predicted values from the proposed porous media (PM) based model and the WS, PT and DP 
models. Table 2.3 indicates that bioavailability predictions from the PM model show good 
agreement with the DP model while a significant discrepancy can be distinguished between PM 
and WS models. The comparison of predicted values with the reported data of bioavailability 
shows that the WS model substantially overestimates drug bioavailability. 
 Table 2.3. Comparison of model predictions with observed values of 
bioavailability associated with seven drugs. 
 Model predictions of Bioavailability (FH) Reported 
Compound PM WS PT DM observationsa 
Naloxone 0.051 0.198 0.018 0.057 0.02 
Verapamil 0.649 0.712 0.667 0.681 0.2±0.12 
Phenacetin 0.067 0.219 0.028 0.074 0.02±0.03 
Lidocaine 0.427 0.539 0.425 0.463 0.24±0.05 
Metoprolol 0.457 0.577 0.480 0.512 0.5±0.11 
Caffeine 0.868 0.951 0.950 0.950 0.92±0.04 
Timolol 0.800 0.855 0.844 0.847 0.61±0.06 
Diazepam 0.978 0.990 0.990 0.990 0.94±0.2 
a Shibata et al., 2002 
 
Table 2.4 shows mean squared prediction errors (MSE) associated with PM, WS, PT and DP 
models for hepatic clearance and bioavailability. It indicates that PM model results in smaller 
MSE for hepatic clearance predictions compared to the other models and the WS, which is a 
physiologically oversimplified model, leads to significantly larger MSE associated with hepatic 
clearance predictions. PM, PT and DP models result in similar MSE while WS causes larger 
MSE for bioavailability predictions. Unlike MSE values, all models have close coefficient of 
determination values for hepatic clearance and bioavailability. Since the proposed numerical 
model takes into account more structural (i.e. porosity, tortousity) and physico-chemical 
parameters (i.e. tissue partition coefficient) compared to the other models, errors associated with 
the parameters are expected to propagate in the solution resulting in larger uncertainties in 
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predictions. However, lower MSE of hepatic clearance predictions and the same MSE of 
bioavailability predictions along with similar coefficient of determination values as other models 
suggest an improvement in mechanistic modeling of hepatic drug elimination using the LVA 
method.  
Table 2.4. Mean squared prediction error (MSE) and coefficient of 
determination (R2) values of hepatic clearance and bioavailability for well-
stirred, parallel tube, dispersion and porous media models. 
 MSE R2 
Model Hepatic 
clearance 
Bioavailability Hepatic 
clearance 
Bioavailability 
Porous media 7.74 0.04 0.91 0.80 
Well stirred 18.41 0.06 0.92 0.82 
Parallel tube 8.15 0.04 0.91 0.81 
Dispersion 9.42 0.04 0.92 0.81 
 
Figure 2.6 depicts the effect of the axial dispersion on the plasma unbound drug concentration 
gradient across the liver at different times. In the absence of axial dispersion, diffusion and 
convection mass transfer are the only mechanisms of drug transport in the liver. As observed 
from Fig. 2.6a, drug is distributed in the liver by the molecular diffusion and the advection 
associated with the blood flow so that the drug can only be distributed within 12 cm of the liver 
in 10 s while hepatocellular drug metabolism is taking place in the liver. After 20 s the drug 
reaches the hepatic vein at the liver outlet and drug concentration begins rising until it reaches 
steady state at 80 s. Unlike advection and diffusion, axial dispersion causes the drug to stretch 
along the liver within seconds. As seen in Fig. 2.6b, the drug reaches the hepatic vein at the liver 
outlet in less than 10 s. In other words, axial dispersion causes the drug to experience less 
residence time during which hepatocellular metabolism of the drug takes place in the liver. Less 
residence time can cause an inadequate time for the drug to reach equilibrium with hepatocytes, 
which, in turn, can reduce the first pass effect within the initial distribution time.  
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Figure 2.6. Plasma unbound drug concentration gradient across the liver at different times 
in the absence (a) and presence (b) of axial dispersion (Dn) for lidocaine. 
Figure 2.7 illustrates the variation of plasma drug concentration at the liver outlet in the 
hepatic vein with time and axial dispersion number. For low levels of axial dispersion, the 
residence time of the drug is about 17 s when the drug reaches the liver outlet followed by a 
sharp increase in the plasma drug concentration. However, as the dispersion number increases 
the residence time of drug in the liver decreases such that at higher dispersion numbers it takes 
only a few seconds for the drug to leave the liver while the plasma drug concentration gradually 
increases at the hepatic vein. The simulated residence time has good agreement with the 
dispersion model predictions of residence time of a drug bolus in the liver reported by Roberts 
and Rowland (1986).  
Figure 2.8 illustrates the sensitivity of the drug concentration gradient across the liver to the 
porosity of the liver at an axial dispersion number of 0.17. An increase in the liver porosity 
causes the plasma drug concentration to elevate across the liver. Likewise, decreases in liver 
porosity results in reductions in the plasma drug concentration across the liver due to the effect 
of the porosity on the sinusoidal blood velocity (pore velocity), which is obtained by the ratio of 
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Figure 2.7. Variation of plasma unbound drug concentration at the hepatic vein versus 
time and axial dispersion number for lidocaine. 
 
 
Figure 2.8. The influence of porosity on plasma unbound drug concentration gradient 
across the liver at different times for lidocaine for axial dispersion number (Dn) of 0.17:  
, =0.06;   , =0.12;   , =0.18. 
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blood Darcy velocity to the porosity. Lower sinusoidal porosity leads to higher pore velocity 
enhancing the effect of the advection term in Eq. (2.8). Larger advection causes the drug to move 
forward faster so that the residence time is reduced and the drug concentration at any position 
across the liver increases during the transient distribution time. Likewise, higher porosity reduces 
the plasma drug concentration at any position during the unsteady state period across the liver; 
however, the effect of porosity on the concentration gradient becomes insignificant at 80 s (Fig. 
2.8). 
Figure 2.9 depicts the sensitivity of the plasma drug concentration gradient across the liver to 
the tissue partition coefficient of lidocaine. Lidocaine’s large tissue partition coefficient results in 
smaller plasma drug concentrations across the liver at all distribution times of the drug. 
According to the definition of the tissue partition coefficient (the ratio of the drug concentration 
in hepatocytes to that in plasma), the larger tissue partition coefficient implies that a larger 
fraction of unbound drug is partitioned into hepatocytes where the drug is metabolized. 
Therefore, for larger hepatic partition coefficient, plasma unbound drug concentration is 
expected to decrease across the liver during the transient drug distribution (Fig. 2.9). However, 
once drug distribution in the liver reaches steady state at 80 s, the effect of tissue partition 
coefficient becomes insignificant. Mathematically this occurs because the accumulation term in 
the right side of the governing equation (Eq. (2.8)) becomes zero at steady state where the effect 
of the tissue partition coefficient is canceled in the model. In other words, the magnitude of the 
tissue partition coefficient has an influence on how fast drug distribution across the liver reaches 
equilibrium.  
Figure 2.10 depicts the affect of intrinsic clearance (Fig. 2.10a) and drug unbound fraction 
(Fig. 2.10b) on the plasma drug concentration gradient across the liver for lidocaine at the axial  
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Figure 2.9. Sensitivity of plasma unbound drug concentration gradient across the liver to 
the partition coefficient for lidocaine for axial dispersion number (Dn) of 0.17:   , 
K*=0.70;   , K*=0.61;  , K*=0.40. 
 
Figure 2.10. Influence of intrinsic clearance (a) and unbound fraction (b) on plasma 
unbound drug concentration gradient across the liver for lidocaine at an axial dispersion 
number of 0.17. 
dispersion number of 0.17. At an unbound fraction of 0.615, the concentration gradient of  
lidocaine across the liver is insignificant for low intrinsic clearance values from 0 to 0.05 Lmin-1. 
This implies that hepatocellular metabolism of the drug is so low that its concentration remains 
relatively unchanged across the liver. However, as intrinsic clearance is enhanced from 0.05 to 
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0.15 Lmin-1, the plasma drug concentration gradient dramatically increases. If the intrinsic 
clearance is increased further, the plasma drug concentration in the second half of the liver is 
significantly reduced so that for intrinsic clearance values greater than 0.2 Lmin-1 the drug 
concentration at the liver outlet is zero implying that all drug is eliminated across the liver. 
Unlike the second half of the liver, the first half of the liver demonstrates more sensitivity to 
higher values (>0.2 Lmin-1) of the intrinsic clearance. Mathematically this is explained by Eq. 
(2.3) where hepatocellular metabolism is a function of both intrinsic clearance and unbound drug 
concentration such that high intrinsic clearance values result in very low unbound drug 
concentrations in the second half of the liver. Hence, in the second half of the liver, despite high 
intrinsic clearance values the rate of metabolism is very low due to very small plasma drug 
concentrations and remains insensitive to intrinsic clearance. However, the first half of the liver 
is subjected to drug enriched blood of the portal vein and hepatic artery and the plasma drug 
concentration is sufficiently high to be sensitive to the higher values of intrinsic clearance.  
Figure 2.10b illustrates the sensitivity of the plasma unbound drug concentration across the 
liver to the unbound fraction of lidocaine at an intrinsic clearance of 29.8 mlmin-1kg-1. With 
higher values of unbound drug fraction, the plasma drug concentration gradient increases so that 
for unbound fractions greater than 0.8 the plasma drug concentration at the last 2 cm of the liver 
is very small. Comparing Fig. 2.10a to Fig. 2.10b indicates that the drug concentration gradient 
across the liver dramatically increases with increases in intrinsic clearance while the unbound 
fraction has a relatively negligible effect on the drug concentration gradient along the liver 
compared to the intrinsic clearance. In addition, no significant change in drug concentration 
occurs in the first 1 cm of liver length when the intrinsic clearance and unbound fraction are 
increased. The dispersion of the drug enriched blood at the region close to the liver inlet 
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suppresses the impact of higher intrinsic clearance and unbound fraction values on the 
concentration gradient in this portion of the liver. 
Figure 2.11 illustrates the variation of hepatic clearance with respect to the hepatic perfusion 
rate and intrinsic clearance. At low values of intrinsic clearance from 0.01 to 0.1 Lmin-1 kg-1 
hepatic perfusion rate has no significant effect on hepatic clearance when perfusion rate 
increases from 1100 to 1800 mlmin-1; however, small changes in intrinsic clearance induce sharp 
increases in hepatic clearance. This suggests that for low intrinsic clearance values the limiting 
factor of hepatic clearance is the hepatocellular enzyme activity represented by the intrinsic 
clearance. For values of the intrinsic clearance greater than 0.1 Lmin-1kg-1 the effect of enzyme 
activity on hepatic clearance becomes insignificant while hepatic clearance increases with  
 
 
Figure 2.11. Variation of hepatic clearance with intrinsic clearance and hepatic perfusion 
rate for lidocaine at a sinusoidal porosity of 0.12 and perfusion rate of 1500 mlmin-1. 
hepatic perfusion rate. This suggests that at higher values of intrinsic clearance the speed of drug 
presentation to the hepatocytes that is determined by perfusion rate is the limiting factor for 
hepatic clearance. 
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Figure 2.12 depicts the influence of the hepatic perfusion rate and intrinsic clearance on the 
hepatic bioavailability of lidocaine. At very low intrinsic clearance values (less than 0.05 Lmin-
1kg-1) hepatic bioavailability is high for all hepatic perfusion rates; the effect of the intrinsic 
clearance predominates although, increasing perfusion rates result in slight increases in 
bioavailability at low intrinsic clearance values. This is likely due to shorter residence times of 
the drug in the liver at higher perfusion rates, which reduces the equilibration time between the 
plasma and hepatocytes. As intrinsic clearance values increase bioavailability decreases 
dramatically such that for intrinsic clearance values greater than 0.2 Lmin-1kg-1 bioavailability 
approaches zero implying all drug is metabolized by the liver during its first pass across the liver.  
 
 
Figure 2.12. Variation of bioavailability with intrinsic clearance and hepatic perfusion rate 
for lidocaine at a sinusoidal porosity of 0.12 and perfusion rate of 1500 mlmin-1. 
Figure 2.13 illustrates the sensitivity of bioavailability to the intrinsic clearance and the 
unbound drug fraction. For very low values of unbound fraction (<0.1) or intrinsic clearance 
(<0.1 Lmin-1kg-1) bioavailability gradually decreases with any increases in either unbound 
fraction or intrinsic clearance. According to Eq. (2.3) which relates the metabolism rate to the 
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intrinsic clearance and unbound fraction, when unbound fraction and intrinsic clearance are very 
low, an increase in only one does not produce a substantial drop in bioavailability due to the 
suppressing effect of the low value of the other variable. However, for higher values (>0.15) of 
unbound fraction and intrinsic clearance, an increase in either one causes a significant drop in 
bioavailability implying that metabolism rate is sufficiently sensitive to the magnitude of the 
values of either unbound fraction or intrinsic clearance. Bioavailability approaches zero when 
unbound fraction and intrinsic clearance gain values greater than 0.5 and 0.2 Lmin-1kg-1, 
respectively. 
 
Figure 2.13. Variation of bioavailability with intrinsic clearance and unbound fraction for 
lidocaine at a sinusoidal porosity of 0.12 and perfusion rate of 1500 mlmin-1. 
The proposed PM model was executed to predict the variation of concentration dependent 
intrinsic clearance across the liver for 1'-hydroxymidazolam (1OH-MDZ) with an affinity term 
(Km) of 0.752 mgL-1, maximum hepatocellular metabolism rate (Vmax) of 0.00173 mg L-1s-1 and 
tissue partition coefficient of 1.25 (Willmann and Edginton, 2007). Figure 2.14 depicts the 
variation of intrinsic clearance and plasma unbound drug concentration with position and time 
across the liver. In Fig. 2.14a, an exponentially increasing trend of the intrinsic clearance can be 
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observed across the liver for all time points during transient drug distribution in the liver. The 
variation of intrinsic clearance is consistent with the plasma unbound drug concentration gradient 
(Fig. 2.14b) and the intrinsic clearance function, Eq. (2.9). In Fig. 2.14b, drug concentration is 
high in the first 8 cm of the liver due to its short distance from the liver inlet where the liver 
receives a drug enriched blood supply; however, the concentration decreases sharply along the 
rest of the liver. According to Eq. (2.9), for concentration dependent intrinsic clearance, a lower 
drug concentration results in a smaller denominator forcing the proportionality to increase 
dramatically as observed in Fig. 2.14a. Subsequently, concentration-dependent intrinsic 
clearance can be observed at all times during drug distribution. The drug concentration across the 
liver increases with time (Fig. 2.14b) causing intrinsic clearance to decrease accordingly (Fig. 
2.14a). As drug distribution across the liver approaches steady state conditions after 40 s, the 
change in the intrinsic clearance becomes insignificant; however, a nonlinear variation of 
intrinsic clearance across the liver occurs all the time. Unlike the proposed PM model, WS, PT  
 
Figure 2.14. Variation of intrinsic clearance (a) and plasma unbound drug concentration of 
1-hydroxymidazolam across the liver at different times.  
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and DP models are unable to predict concentration dependent intrinsic clearance so that an 
uncertainty will exist in the predictions. In addition, as the affinity term value of 0.752 mgL-1 is 
comparable to the lowest drug concentration (0.02103 mgL-1) occurring at 20 s in the liver outlet, 
the influence of the drug concentration on the magnitude of the denominator of Eq. (2.9) cannot 
be neglected. Therefore, the simulation of the hepatic drug elimination of 1OH-MDZ must take 
into account the concentration dependent intrinsic clearance.  
  
2.4. Conclusion 
According to the liver permeability, sinusoidal diameter, the size of acinus and the liver 
equivalent length, the validity condition of LVA method was satisfied by the length scales of the 
liver tissue as a porous medium. Applying LVA method and local equilibrium, a governing 
equation taking into account the liver structural characteristics, the drug physico-chemical 
properties and the mass transport properties was developed and validated using reported 
observations of hepatic clearance (R2=0.91) and oral bioavailability (R2=0.80) of eight drugs. 
The proposed model suggests similar coefficient of determination values but smaller MSE for 
predicted values of hepatic clearance compared to WS, PT and DP models. MSE values of 
bioavailability are similar between PT, DP and the proposed mechanistic model; however, WS 
model possesses a larger MSE. 
The simulation of drug distribution at different levels of axial dispersion numbers indicates 
that the influence of axial dispersion on the drug concentration gradient and residence time of the 
drug across the liver is very significant. Therefore, excluding the axial dispersion from a model 
(i.e. WS and PT) can inherently cause an uncertainty in model predictions. A sensitivity analysis 
revealed that an increase in the liver porosity, which reduces the sinusoidal pore velocity of the 
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blood, causes the drug concentration gradient to decrease across the liver. The analysis also 
shows that an increase in the hepatic tissue partition coefficient elevates the drug concentration 
gradient across the liver and the drug concentration gradient across the liver is very sensitive to 
intrinsic clearance such that hepatic drug elimination in the second half of the liver dramatically 
increases with the intrinsic clearance. Although the influence of unbound fraction on the drug 
concentration gradient is appreciable, the effect of intrinsic clearance is significantly higher than 
the unbound fraction. The analysis also indicates that the influence of perfusion rate on the 
hepatic clearance becomes distinctive at larger values of intrinsic clearance while no limiting 
effect of the perfusion rate is observed at low intrinsic clearance.  
Sensitivity analysis revealed that the bioavailability is sensitive to the interaction between 
unbound fraction and intrinsic clearance. For very low values of unbound fraction and intrinsic 
clearance, if either one is increased, the low value of the other variable suppresses the effect of 
the other one. However, with higher values a significant drop in bioavailability is observed with 
increases in either intrinsic clearance or unbound fraction. However, when the values are 
sufficiently high, bioavailability approaches zero and is insensitive to unbound fraction and 
intrinsic clearance.  
Unlike WS, PT and DP models, the proposed PM model takes into account the nonlinear-
concentration dependent intrinsic clearance based on which the effect of changes of drug 
concentration on the hepatocellular metabolism and hepatic drug elimination can be more 
precisely analyzed. In addition, the uncertainty associated with the assumption of a constant 
intrinsic clearance across the liver is minimized using PM model. 
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CHAPTER 3 
GENERAL DISCUSSION 
 
 
3.1 Introduction 
A better insight to the body processes and a significant cost reduction in pharmaceutical 
industries can be facilitated by physiological models that integrate the mechanisms associated 
with pharmacokinetics (PK) and pharmacodynamics (PD) processes. The hepatic drug 
elimination process the efficiency of which is described by hepatic clearance s is considered as a 
major PK process that reduces the plasma drug concentration particularly for lipophilic drugs. 
Several physiological models including well-stirred (WS), distributed sinusoidal perfusion 
(DSP), parallel tube (PT), dispersion (DP), interconnected tube (ICT), and tank-in series models 
have been developed to describe the hepatic elimination process. Simplifications and 
assumptions made to develop and solve models are the major sources of uncertainties of 
predictions. To improve the predictability of a mechanistic model for hepatic drug elimination, 
the mathematical formulation must be consistent with the physiological and physical phenomena 
taking place in the liver. An ability to make robust predictions of drug elimination by the liver 
requires a mechanistic model that simulates real physiological events in the liver.  
Since the liver tissue is inherently porous and highly perfused, a porous media approach can 
be a promising approach towards analyzing the hepatic drug elimination process. Thus, local 
volume averaging (LVA) method was used for developing a governing equation to describe the 
 76
drug concentration gradient across the liver and to predict hepatic clearance and bioavailability. 
The predictability of the mechanistic model was evaluated and then the model was employed to 
perform sensitivity analyses of the hepatic drug elimination process at different conditions. The 
objective of this chapter is to integrate findings of this study, to discuss the limitations of the 
proposed model and to suggest future efforts for improving the model.  
 
3.2 Porous media physiological model 
In order to apply LVA method to a porous medium, the LVA validity condition must be 
evaluated according to the porous medium length scales. The length scales of the liver, Brinkman 
screening length of hepatocytes (5.710-7 m) (Smye et al., 2007), sinusoidal diameter (610-5 m) 
(Zhou et al., 2007), the linear size of an acinus (610-4 m) (Smye et al., 2007), and the liver 
equivalent length (210-1 m) (Zhou et al., 2007), satisfied the validity condition of Eq. (2.2) 
(Kaviany, 1995) as 5.710-7<<610-5<610-4<<210-1 m implying that LVA method was 
applicable to the liver as a porous medium.  
The proposed mechanistic model was able to take into account liver porosity, tortuosity, 
permeability, unbound drug fraction, hepatic tissue partition coefficient, drug-plasma diffusivity, 
axial/radial dispersion and nonlinear hepatocellular metabolism parameters for describing the 
drug concentration gradient across the liver and predicting hepatic clearance and bioavailability. 
A mesh and time step size sensitivity analyses revealed that 350 nodes at a time step size of 1 s 
were adequate for sufficiently high accuracy and consistency with a reasonable speed of solution. 
In order to validate the model, the predicted results were compared to the values of hepatic 
clearance and bioavailability observed for different drugs with low and high hepatic intrinsic 
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clearance. As well, the predictability of the proposed model was compared to that of WS, PT and 
DP models. 
3.2.1 Validating the proposed model 
The predicted values of hepatic clearance and bioavailability were compared to the observed 
values reported by Shibata et al. (2002) for naloxone, verapamil, phenacetin, lidocaine, 
metoprolol, caffeine, timolol and diazepam at the hepatic perfusion rate of 1500 mlmin-1for a 70 
kg male subject. A coefficient of determination of 0.91 indicated a very good agreement between 
predictions and observations of the hepatic clearance; however, the model underestimated the 
hepatic clearance of timolol and verapamil and overestimated the hepatic clearance of 
phenacetin. The underestimation of the hepatic clearance of timolol may be associated with the 
genetic polymorphism of timolol hepatocellular metabolism which can cause significant 
variability in the population (Volotinen et al., 2007). Since the PK properties used in the 
simulation were not population based, an inherent uncertainty was induced in the estimations of 
the hepatic clearance of timolol. The large interindividual differences (more than five fold) in 
oral area under the curve (AUC) of verapamil (Eichelbaum et al., 1981a; Eichelbaum et al., 
1981b; Lin and Lu, 2001) could have a significant contribution to the uncertainty of the 
estimations of intrinsic clearance of verapamil, which was used for the simulation in this study. 
Since the hepatic clearance is very sensitive to the variation of intrinsic clearance (Fig. 2.10a), 
the uncertainty of the intrinsic clearance of verapamil due to the large interindividual variability, 
can be the potential source of uncertainty in the estimation of hepatic clearance of verapamil.  
The proposed model predicted bioavailability well showing a relatively good agreement with 
observed values with a coefficient of determination of 0.80. Since the bioavailability was 
calculated based on the hepatic clearance, Eq. (2.19), the uncertainty associated with the 
estimated hepatic clearance propagated into the predicted bioavailability values. In addition, the 
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reported values were based on oral bioavailability while the proposed model could estimate only 
the hepatic bioavailability. Therefore, lacking the information of drug loss in the intestine and 
portal vein, predicted values of bioavailability inherently had a discrepancy with the observed 
values of oral bioavailability. 
3.2.2 PM model predictability compared to WS, PT and DP models 
The proposed PM model indicated smaller mean square prediction error (MSE) for hepatic 
clearance predictions compared to WS, PT and DP models. The physiologically oversimplified 
WS model led to significantly larger MSE in hepatic clearance predictions. MSE values of 
bioavailability predictions were similar for PM, PT and DP models while WS model resulted in 
larger MSE.  All models indicated very close coefficient of determination values for hepatic 
clearance as well as bioavailability. Also, all coefficient of determination values for the hepatic 
clearance were larger than those for bioavailability. Since the proposed numerical model takes 
into account more structural (i.e. porosity, tortousity) and physico-chemical parameters (i.e. 
tissue partition coefficient) compared to the other models, more errors associated with the 
parameters were expected to eventually appear in the predictions. However, despite several 
mechanistic parameters in the model, the proposed model resulted in smaller MSE with similar 
coefficient of determination for predicted values of hepatic clearance compared to WS, PT and 
DP models. This analysis suggests a potential improvement in predictability of the hepatic drug 
elimination if a porous media approach is adopted. 
 
3.3 Simulation and sensitivity analyses 
One of the applications of the validated model is to simulate the drug concentration 
distribution profile across the liver. Also, the proposed model was used for assessing the 
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sensitivity of the hepatic drug elimination process to drug physico-chemical properties as well as 
liver physiological parameters and the transport properties. 
3.3.1 The effect of axial dispersion on the drug distribution profile 
Simulation results indicated that axial dispersion has a significant effect on drug distribution 
across the liver. Unlike advection and diffusion, axial dispersion causes the drug to be distributed 
along the liver within seconds. In the absence of dispersion effect, it takes the drug about 20 s to 
reach the hepatic vein at the liver outlet; however, with an axial dispersion number of 0.17, the 
drug reaches the hepatic vein within less than 10 s. Axial dispersion causes the drug to 
experience less residence time which causes an inadequate time for the drug to reach equilibrium 
with hepatocytes, which, in turn, can reduce the first pass effect within the initial distribution 
time. For high extraction ratio drugs which are highly extracted as passing through the liver, the 
delay in plasma-tissue equilibrium caused by the axial dispersion can significantly enhance the 
bioavailability of the drug. In addition, when only diffusion and advection are the major transport 
mechanisms of the drug in the liver, the maximum drug concentration gradient across the liver 
remains high during the distribution time. In contrast, in the presence of dispersion effect the 
maximum drug concentration gradient is low. 
3.3.2 The influence of the liver porosity on the liver drug distribution profile 
Simulation results for different levels of the liver porosity revealed that an increase in the liver 
porosity decreases the plasma drug concentration gradient across the liver and vice versa for 
decreasing the liver porosity. The simulation indicated that the influence of the porosity on the 
drug distribution in the liver can be attributed to the variation of sinusoidal blood velocity (pore 
velocity) with porosity. Lower sinusoidal porosity leads to higher pore velocity enhancing the 
effect of the advection. Larger advection effect leads to a faster drug movement towards the 
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hepatic vein such that the residence time is reduced and the drug concentration at any position 
across the liver increases during the transient distribution time. 
3.3.3 The effect of tissue partition coefficient on the liver drug distribution profile 
Simulation of drug distribution across the liver at different values of hepatic tissue partition 
coefficient indicated that larger tissue partition coefficient values lowered the plasma drug 
concentration for all positions along the liver at all distribution times. It was physiologically 
consistent with the fact that the drug is partitioned into the liver tissue when the partition 
coefficient increases. Indeed, larger partition coefficient reduces the plasma drug concentration 
as more drug is partitioned into hepatocytes. Simulation analysis also revealed that once drug 
distribution in the liver reached steady state where the plasma concentration did not change with 
time across the liver, the role of hepatic tissue partition coefficient became insignificant.   
3.3.4 The sensitivity of liver drug distribution profile to intrinsic clearance 
Simulation of hepatic drug elimination indicated that as the intrinsic clearance increased from 
very low to low values (from 0.05 to 0.15 Lmin-1), the plasma drug concentration gradient along 
the liver increased dramatically. When the intrinsic clearance was increased further (greater than 
0.2 Lmin-1), the plasma drug concentration in the second half of the liver approached zero. It 
implied that the entire drug was eliminated while traveling through the liver if the intrinsic 
clearance is greater than 0.2 Lmin-1. Consequently, unlike the second half of the liver, the first 
half of the liver was found to be more sensitive to high intrinsic clearance values. 
3.3.5 The sensitivity of liver drug distribution profile to unbound fraction 
The plasma drug concentration gradient increased with unbound fraction; however, the 
sensitivity of plasma drug concentration to the unbound fraction was not as significant as that to 
the intrinsic clearance.  The unbound fraction values greater than 0.8 led to significantly low 
plasma drug concentration at the last 2 cm of the liver. 
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3.3.6 The sensitivity of hepatic clearance to perfusion rate and intrinsic clearance 
The sensitivity analysis of hepatic clearance with respect to the perfusion rate and intrinsic 
clearance indicated that for low values of the intrinsic clearance (from 0.01 to 0.1 Lmin-1 kg-1), 
hepatic clearance was not sensitive to the perfusion rate but highly sensitive to the intrinsic 
clearance. As the value of the intrinsic clearance increased, the hepatic clearance was more 
sensitive to the perfusion rate and less sensitive to the intrinsic clearance. This suggests that at 
higher values of intrinsic clearance the speed of drug presentation to the hepatocytes that is 
determined by perfusion rate is the limiting factor for hepatic clearance which is consistent with 
other model predictions (i.e. WS, DP models).  
3.3.7 The sensitivity of bioavailability to perfusion rate and intrinsic clearance 
The hepatic bioavailability was found to be very high at low intrinsic clearance for all levels 
of perfusion rate. As intrinsic clearance increased, bioavailability decreased dramatically such 
that for intrinsic clearance values greater than 0.2 Lmin-1kg-1 bioavailability approached zero 
implying the entire drug is metabolized by the liver during its first pass across the liver. 
Although bioavailability was slightly sensitive to the perfusion rate at high intrinsic clearance 
(less than 0.2 Lmin-1kg-1), the influence of intrinsic clearance on bioavailability was predominant 
over the perfusion rate. The sensitivity analysis results had a very agreement with the predictions 
from WS, PT and DP models indicating the validity of PM model predictability.   
3.3.8 The influence of unbound fraction and intrinsic clearance on bioavailability 
For very low unbound fraction (i.e. <0.1) or intrinsic clearance (i.e. <0.1 Lmin-1kg-1) 
bioavailability gradually decreased with unbound fraction or intrinsic clearance. When unbound 
fraction and intrinsic clearance were very low, an increase in only one caused no substantial drop 
in bioavailability due to the suppressing effect of the low value of the other variable. However, 
for higher unbound fraction (i.e. >0.15) and intrinsic clearance (i.e. >0.15 Lmin-1kg-1), any 
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increase in the either unbound fraction or intrinsic clearance induced a significant drop in 
bioavailability indicating that hepatocellular metabolism was sensitive to the magnitude of 
unbound fraction and intrinsic clearance. Other models suggest the same results as the simulation 
results from PM model. Bioavailability approached zero when unbound fraction and intrinsic 
clearance were greater than 0.5 and 0.2 Lmin-1kg-1, respectively. 
3.3.9 Simulation of hepatic drug elimination with nonlinear intrinsic clearance 
Simulation revealed an exponentially increasing trend of the intrinsic clearance along the liver 
for all time points during transient drug distribution in the liver. The variation of concentration 
dependent intrinsic clearance was consistent with the decreasing trend of plasma unbound drug 
concentration gradient as well as the intrinsic clearance function (Eq. (2.9)). The drug 
concentration across the liver increased with time causing intrinsic clearance to decrease 
according to the intrinsic clearance function, Eq. (2.9). As the drug distribution in the liver 
approached steady state in which the plasma drug concentration remained unchanged with time 
across the liver, the change in the intrinsic clearance remained insignificant; however, the 
intrinsic clearance had a nonlinear variation across the liver at all times. In addition, the 
simulation results indicated that if the affinity term of a drug (i.e. 1'-hydroxymidazolam) is 
comparable to the lowest drug concentration in the liver (i.e. KM is equivalent to Cu), the fact of 
concentration-dependent intrinsic clearance must be taken into account for simulation of hepatic 
drug elimination. 
 
3.4 General conclusions 
The proposed porous media approach was successfully evaluated and applied for modeling of 
drug elimination by the liver. In addition to mass transport and physico-chemical properties, 
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some structural properties of the liver including tortuosity and porosity were effectively included 
in the model. It was demonstrated that the LVA method was valid for modeling the hepatic drug 
elimination process. Unlike WS, PT, ICT, DP, and tank-in-series models, the proposed PM 
model demonstrated a successful ability to simulate hepatic drug elimination with concentration-
dependent intrinsic clearance. Compared to WS, PT and DP models, the proposed model resulted 
in lower MSE values associated with the hepatic clearance prediction. It suggested an 
improvement in model predictability for hepatic clearance. A very good agreement between 
predicted results from PM model and observations as well as the predictions from WS, PT and 
DP models indicated that the reliability of the application of a porous media viewpoint to 
analysis of the hepatic drug elimination process. 
Excluding the axial dispersion from a model (i.e. WS and PT) inherently causes uncertainty in 
model predictions. Porosity also influenced the sinusoidal blood velocity such that an increase in 
liver porosity caused a reduction in plasma drug concentration across the liver. Although the 
influence of unbound fraction on the drug concentration gradient is appreciable, the effect of 
intrinsic clearance was significantly higher than the unbound fraction. The influence of perfusion 
rate on the hepatic clearance became distinctive at larger values of intrinsic clearance while no 
limiting effect of the perfusion rate was observed at low intrinsic clearance. Also, sensitivity 
analysis revealed that the bioavailability was sensitive to the interaction between unbound 
fraction and intrinsic clearance. In addition, the uncertainty associated with the assumption of a 
constant intrinsic clearance can be avoided if PM model is employed. 
 
3.5 PM model limitations and future studies 
A departure from reported observations may exist if the diffusional mass transfer resistance 
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across the hepatocellular membrane is higher than convection mass transfer resistance. This 
situation violates the assumption of a local equilibrium in the differential element resulting in 
significant error in the predictions. The assumption of local equilibrium represented by the tissue 
partition coefficient also precludes addition of the role of transporters and their potential 
contribution as a rate-limiting process in the intrinsic clearance of drugs. 
The proposed model can be coupled with an absorption model in order to provide a dynamic 
simulation of the hepatic elimination process following an oral administration. Furthermore, the 
model can be coupled with models of major body organs (i.e. kidneys, brain, lungs, gastro 
intestine, muscles) such that the whole body PK can be explored. Then the whole body PK will 
be used for a better transition from preclinical studies (animal studies) to clinical studies where 
the model can be applied for investigating the optimum dose. As well, the model will contribute 
to better understanding different factors affecting the overall disposition (i.e. rate limiting 
parameters).  
The model’s ability to describe the time dependent drug concentration with position across the 
liver makes the model potentially useful for investigating the effect of a pathological deficiency 
(i.e. shunting) on the pattern of drug distribution across the liver. Part of the liver tissue can be 
virtually disabled in the model by defining the starting and ending positions associated with 
shunting. In this way, the defined location will not contribute the hepatic metabolism of the drug 
as the blood flow and enzyme activity attributed to the location are set to zero in the model. In 
addition, the model can potentially accommodate the zonal distribution of Phase I and Phase II 
enzymes in liver acini if solved two dimensionally. Three zones with appropriate boundary 
conditions can be defined along y direction of the liver geometry while three enzymatic activity 
characteristics (i.e. intrinsic clearance, affinity term, maximum metabolism rate capacity) are 
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specified to each zone. Two dimensional solution of the model will take into account the zonal 
effects on the hepatic dug elimination. 
Future refinements of the model will address the incorporation of mass transfer resistance 
associated with transporters and mass diffusion across the hepatocellular membranes. In 
addition, intrinsic average properties can be used for developing a set of two coupled governing 
partial differential equations for hepatocytes and blood flow such that the surface area of 
sinusoids in acini, mass transfer resistance in space of disse, and the drug concentration gradient 
across hepatocytes and sinusoids are taken into account. 
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APPENDIX: 
 
Discretized equations of the partial differential governing equation (Eq. 2.8) 
Node i=1: 
As the node 1 is subjected to irregular boundary, the non-uniform grid size based finite 
difference must be applied to the governing equation. The tailor’s series expansion of variable C 
at node i+1 with a node size of x, and at node i-1 with a node size of x/2 are given as: 
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Multiplying the first equation by 1/2 and adding the result to the second equation results in: 
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 Rearranging the result for the second derivative term leads to  the approximation of the second 
derivative of C with respect to x with non uniform grid sizes of x and x/2 as: 
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If the above equation is applied to the diffusion term in Eq. (2.8), and the convection term is 
discretized using backward finite difference, the discretized form of Eq. (2.8) based on implicit 
finite difference with non uniform grid size at the boundary will be as: 
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Nodes 1< i  N: 
Applying central finite difference to the diffusion term and backward finite difference to the 
convection term results in the discrete form of Eq. (2.8) for nodes 2 to N as: 
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Node i=N+1: 
Defining a fictitious node of N+1 at the outlet (the second boundary) and applying no-diffusion 
mass flux condition, the algebraic finite difference equation at the virtual node of N+1 will be as:  
       






















f(C)Cl
CK
V
f(C)ClCl
Cl
CCl
CC
xf
uCC
x
D
CC
t
f
K
j
iM
invivoint
j
N
j
N
j
N
Bu
Bj
N
j
N
AB
j
N
j
N
Bu
int1
max
int
int
1int
1
)(
12
1
11
)(
*
 if    
  if        
:Where
22
1 

 
